Document:

EX-10.24

 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and
filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 Exhibit
10.24 
 PATENT AND TECHNOLOGY LICENSE 

AND MATERIALS TRANSFER AGREEMENT 

BY AND BETWEEN 
 THE
JOHNS HOPKINS UNIVERSITY 
 & 

ADURO BIOTECH, INC. 

JHU Agreement: # -A21083 

 PATENT AND TECHNOLOGY LICENSE AND 

MATERIALS TRANSFER AGREEMENT 

THIS PATENT AND TECHNOLOGY LICENSE AND MATERIALS TRANSFER AGREEMENT (this “Agreement”) is dated as of January 31, 2013
(the “Effective Date”) and entered into by and between THE JOHNS HOPKINS UNIVERSITY, a Maryland corporation having an address at 3400 N. Charles Street, Baltimore, Maryland, 21218-2695 (“JHU”) and ADURO BIOTECH,
INC., a Delaware corporation having an address at 626 Bancroft Way, Suite 3C, Berkeley, California 94710-2225 (“Company”): 

RECITALS 
 WHEREAS, as a
center for research and education, JHU is interested in licensing intellectual property and proprietary materials in a manner that will benefit the public by facilitating the distribution of useful products and the utilization of new processes, but
is without capacity to commercially develop, manufacture, and distribute any such products or processes; and 
 WHEREAS, valuable
invention(s) were developed during the course of research at JHU and are listed as follows: “Formulation of Toll-like Receptor Ligand with Whole Cell Tumor Vaccine to Enhance Anti-tumor Responses” (JHU Ref No. C05152) invented by Drs. Kim
Young, Megan Davis, Charles Drake and Drew Pardoll; “Combinatorial TEGVAX with Blockade of Immune Checkpoint Pathways Augments Anti-tumor Responses In Vivo” (JHU Ref No. C11641) invented by Drs. Kim Young, Juan Fu and Drew Pardoll; and
“GVAX Formulated with Cyclic Dinucleotide (STINGVAX) is a Potent Cancer Vaccine” (JHU Ref No. C12043) invented by Juan Fu and Drew Pardoll; and, 

WHEREAS, JHU has certain rights in GVAX cell lines and technologies described in JHU Ref No. C12266 “Breast Cancer Cell Lines”
disclosed by Leisha Emens; JHU Ref#: C12273 “Myeloma Cell Lines” disclosed by Ivan Borrello and Kimberly Noonan; JHU Ref#: C12276 “An Allogeneic Colon Cancer Cell Vaccine Administered with a GM-CSF Producing Bystander Cell Line”
disclosed by Lei Zheng, Richard Schulick, Drew Pardoll, Elizabeth Jaffee and Daniel Laheru; JHU Ref No. C12267 “IND filing ref#: BB IND 11019” disclosed by Leisha Emens; JHU Ref#: C12274 “Myeloma IND Filing” disclosed by Ivan
Borrello and Kimberly Noonan; JHU Ref#: C12275 “Prostate cancer IND Filing” disclosed by George Drake; (all hereinafter, “Inventors”) 

WHEREAS, JHU has acquired rights, title and interest, with the exception of certain retained rights by the United States Government and joint
rights of Company, to the inventions as part of the Licensed Patent Rights; and 
 WHEREAS, Company desires to obtain certain rights in such
patent rights, cell lines, and technology as herein provided, and to commercially develop, manufacture, use and distribute products and processes based upon or embodying said valuable inventions, cell lines, and/or technologies throughout the United
States; 
  
 [*] = Certain confidential information contained in this document,
marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

  
 1 

 NOW THEREFORE, in consideration of the premises and the mutual promises and covenants contained
in this Agreement, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree as follows: 

ARTICLE 1 
 DEFINITIONS

 All references to particular Exhibits, Articles or Sections shall mean the Exhibits to, and Articles and Sections of, this Agreement,
unless otherwise specified. For the purposes of this Agreement and the Exhibits hereto, the following words and phrases shall have the following meanings: 

1.1 “ADDITIONAL CELL LINES” shall have the meaning set forth in Section 5.8. 

1.2 “AFFILIATE(S)” means any corporation, company, partnership, joint venture or other entity which controls or is controlled
by Company. Control shall mean the direct or indirect ownership of at least fifty percent (50%) of the securities or other ownership interests representing the equity, voting stock, general partnership or membership interest of such entity.

 1.3 “CELL LINES” shall mean cell lines listed in Exhibit B hereto. Cell Lines shall also include any additional
cell lines transferred to Company pursuant to Section 5.8 of this Agreement. 
 1.4 “COMBINATION PRODUCT” shall have
the meaning set forth in Section 1.18. 
 1.5 “DEVELOPED IP” shall have the meaning set forth in Section 2.5.

 1.6 “EUROPEAN UNION” shall mean the member states listed as member states in www.europa.eu or any successor web
site. 
 1.7 “FDA” shall mean the U.S. Food and Drug Administration. 

1.8 “FIELD” shall mean any use of GVAX-related products (including without limitation GVAX in combination with other
elements) including, without limitation, human, veterinarian or diagnostic uses. 
 1.9 “FIRST COMMERCIAL SALE” shall mean,
with respect to any Licensed Product or Licensed Service and any country of the world, the first sale of such Licensed Product or Licensed Service under this Agreement by Company, its Affiliates, or Sublicensee(s) to a non-affiliate third party in
such country. 
 1.10 “GVAX” shall mean an allogeneic cell line or cell lines of the same tumor type as the cancer of
interest that (i) has been genetically modified to express GM-CSF, and (ii) has been rendered proliferation-incompetent by irradiation. 

1.11 “INDEMNITEE” shall have the meaning set forth in Section 7.1. 

 
 [*] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

  
 2 

 1.12 “LICENSED IP” means the Licensed Patent Rights, Licensed Technology, and
Cell Lines. For clarity, Licensed IP shall not include (i) any information, technology, patent rights, materials, and cell lines already owned or controlled by Company or to which Company already has access, or independently developed by
Company, (ii) any information, technology, patent rights, materials, and cell lines licensed to, provided to or to which access is given, or owned by the Company under an agreement other than this Agreement, and (iii) any intellectual
property that is provided to Company as part of this Agreement, but is not accepted by Company or is removed from this Agreement by the Company by written thirty (30) days’ notice from the Company to JHU. 

1.13 “LICENSED PATENT RIGHTS” include (i) the patent applications listed in
Exhibit A hereto, and (ii) any patent or patent application claiming priority thereto or common priority therewith including all divisions, continuations-in-part (but only to the extent that the claims of each such continuation-in-part
application are directed to subject matter specifically described in (i)), and all divisions and continuations thereof, all U.S. patents issuing thereon and reissues, reexaminations, renewals and extensions thereof, any corresponding foreign patent
applications, and any patents, or other equivalent foreign patent rights issuing, granted or registered thereon. 
 1.14 “LICENSED
PRODUCT(S)” as used herein in either singular or plural shall mean any process or method, material, compositions, drug, or other product, the manufacture, use or sale of which by Company, its Affiliates and/or Sublicensees (i) would
constitute, but for a license granted to Company, an infringement of a Valid Claim of Licensed Patent Rights (infringement shall include, but is not limited to, direct, contributory, or inducement to infringe) or (ii) necessarily uses or
incorporates Licensed Technology and/or Cell Lines. 
 1.15 “LICENSED SERVICE(S)” as used herein in either singular or
plural shall mean the performance on behalf of a third party by Company, its Affiliates and/or Sublicensees of any method or the manufacture of any product or the use of any product or composition which (i) would constitute, but for a license
granted to Company, an infringement of a Valid Claim of Licensed Patent Rights (infringement shall include, but not be limited to, direct, contributory or inducement to infringe) or (ii) necessarily uses or incorporates Licensed Technology
and/or Cell Lines. 
 1.16 “LICENSED TECHNOLOGY” as used herein includes all of JHU’s technology, to the extent
reasonably required to practice or use, or otherwise specific to, the Licensed Patent Rights, Cell Lines, or GVAX including, without limitation, JHU’s unpatented, proprietary data, results, formulae, designs, specifications, methods, processes,
formulations, techniques, know-how, technical information (including, without limitation, structural and functional information), process information, regulatory filings, drug master files, pre-clinical information, clinical information, and any and
all proprietary biological, chemical, pharmacological, toxicological, pre-clinical, clinical, assay, chemistry, manufacturing and control data created, developed, and fixed in any tangible medium of expression solely by one or more of the JHU
inventors prior to the Effective Date of this Agreement and that is owned by JHU and is not subject to any third party encumbrance that would prevent transfer to Company and to the extent that the provision of such information to Company does not
violate the Health Insurance Portability and Accountability Act 
  
 [*] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 

  
 3 

 
(HIPAA) privacy rules. Licensed Technology specifically excludes Licensed Patents and Cell Lines. While such information may be provided as part of the Technology Transfer, Licensed Technology
shall not include any information which: (a) is within the public domain prior to the time of provision by JHU or thereafter becomes within the public domain other than as a result of provision to a third party by Company or any of its
representatives in violation of this Agreement; (b) was, on or before the date of provision to Company in the possession of Company as evidenced by records, however maintained; (c) is acquired by Company from a third party having the right
to provide the same; or (d) is hereafter developed by Company, as evidenced by records, however maintained. Licensed Technology existing as of the Effective Date of this Agreement includes, without limitation, the Licensed Technology listed in
Exhibit C hereto. 
 1.17 “MINIMUM ANNUAL ROYALTIES” shall have the meaning set forth in Section 3.3. 

1.18 “NET SALES REVENUES” shall mean consideration received by Company, its Affiliates and Sublicensees from the sale of
Licensed Products in the first arm’s length transaction, less deductions appropriate under US GAAP (to the extent not already reflected in the cash received) including, without limitation, administrative warehouse and service fees paid by
Company for third party commercial wholesalers and distributors, payments that are returned by Company pursuant to applicable law, trade discounts or rebates allowed, refunds, returns and recalls, and sales, use, VAT, tariff, import/export duties,
or other excise taxes that to be collected by Company and paid to governmental authorities or are invoiced to purchaser and/or paid and remitted by Company to third parties in connection with sale of such Licensed Product. Net Sales Revenues of a
Licensed Product with more than one therapeutically active component (“Combination Product”) sold by Company, its Sublicensees or Affiliates shall be calculated by multiplying the Net Sales Revenue of the Combination Product by the
fraction A/A+B, where A is the number of all therapeutically active components covered by the Licensed IP hereunder in the Combination Product, and B is the number of all other therapeutically active components in the Combination Product which are
not covered by the Licensed IP hereunder. If Licensed Product is given away as part of a kit, or it is not sold but accompanies a product that is sold, then the sale price for the Licensed Product shall be deemed to be the proportional amount of the
sale price based on a comparison at the fair market value of each component of the kit or of all products included in the sale. Any noncash consideration received in consideration for the sale of a Licensed Product will be reasonably valued by
Company at fair market value. 
 1.19 “NET SERVICE REVENUES” shall mean cash received by Company or its Affiliates or
Sublicensees for the performance of Licensed Services in the first arm’s length transaction, less deductions appropriate under US GAAP (to the extent not already reflected in the cash received) such as sales and/or use taxes imposed upon
and with specific reference to the Licensed Services. Net Service Revenues of a combination service sold by Company, its Sublicensee(s) and/or its Affiliates shall be calculated by: (i) subtracting the separately available price of therapeutic
and/or prophylactic in the combination service from the Net Service Revenues; or (ii) if such therapeutic and/or prophylactic is not sold separately the parties agree to negotiate a reduction in the royalty rate to reflect the fair value that
the Licensed Services attributed to the overall combination service sold, but in no event shall the royalty rates be reduced by greater than [ * ]. In the event that such therapeutic and/or prophylactic is a Licensed 

 
 [*] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

  
 4 

 
Product, the Net Service Revenues for purposes of royalty payments shall be based on the sales revenues and fees received from sale of the entire combination service, provided
however, that the running royalty hereunder shall be imposed only once with respect to the sale of a single unit of a Licensed Product. Any noncash consideration received in consideration for the sale of a Licensed Services will be reasonably
valued by Company at fair market value. 
 1.20 “PHASE 1 CLINICAL TRIAL” shall mean the initial introduction of an
investigational new drug into humans in a study designed to determine the metabolism and pharmacological actions of the drug in humans, the side effects associated with the increasing doses, and, if possible, to gain early evidence of effectiveness,
which study meets the requirements of 21 C.F.R. § 312.21(a), as may be amended from time to time, or a similar clinical study prescribed by the regulatory authorities in a market other than the United States. 

1.21 “PHASE 2 CLINICAL TRIAL” shall mean clinical studies conducted to evaluate the effectiveness of the drug for a
particular indication or indications in patients with the disease or condition under study and to determine the common short-term side effects and risks associated with the drug, which studies meet the requirements of 21 C.F.R. § 312.21(b), as
may be amended from time to time, or a similar clinical study prescribed by the regulatory authorities in a market other than the United States. 

1.22 “PHASE 3 CLINICAL TRIAL” shall mean expanded clinical studies intended to gather the additional information about
effectiveness and safety that is needed to evaluate the overall benefit-risk relationship of the drug and to provide an adequate basis for the physician labeling, which trials meet the requirements of 21 C.F.R. § 312.21(c), or a similar
clinical study prescribed by the regulatory authorities in a market other than the United States. 
 1.23 “REGULATORY
APPROVAL” shall mean all approvals, including licenses, registrations, and authorizations, of all governmental agencies in a country necessary for the manufacture, use or sale of a Licensed Product or Licensed Service in the applicable
country. As used herein, Regulatory Approval shall not include pricing or reimbursement approval. 
 1.24 “STINGVAX” shall
mean GVAX plus cyclic dinucleotides and/or derivatives and/or formulations of cyclic dinucleotides. 
 1.25 “SUBLICENSE
INCOME” shall have the meaning set forth in Section 3.8. 
 1.26 “SUBLICENSEE(S)” as used herein in either
singular or plural shall mean any person or entity other than an Affiliate to which Company has granted a sublicense under this Agreement. Sublicensee(s) shall also include any person or entity to which Company’s Sublicensee(s) has granted a
sublicense subject to JHU’s approval and the conditions hereunder. 
 1.27 “TEGVAX” shall mean GVAX plus toll-like
receptor ligands. 
 1.28 “TERRITORY” shall mean world-wide. 

1.29 “VALID CLAIM” shall mean those claims of a patent or patent application in any country that (i) have not expired;
(ii) have not been disclaimed; (iii) have not been revoked, 
  
 [*] =
Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 5 

 
held invalid, or otherwise declared unenforceable or not allowable by a tribunal or patent authority of competent jurisdiction over such claim in such country from which no further appeal has or
may be taken; and (iv) in the case of a pending application, was filed and is being prosecuted in good faith towards allowance for not more than [ * ] years. 

ARTICLE 2 
 LICENSE GRANT

 2.1 Grant. Subject to the terms and conditions of this Agreement, JHU hereby grants to Company (i) an exclusive license
with the right to grant sublicenses in accordance with Section 2.2, hereof, to the Licensed Patent Rights and (ii) an exclusive license with the right to grant sublicenses in accordance with Section 2.2, hereof, to JHU’s interest
in Cell Lines; to make, have made, use, have used, sell, offer for sale, have sold, import, have imported, develop and commercialize, Licensed Products and to provide Licensed Services in the Territory for the Field and (iii) a nonexclusive
license, with the right to grant sublicenses in accordance with Section 2.2, hereof, to use Licensed Technology to make, have made, use, have used, sell, offer for sale and have sold, import, have imported, develop and commercialize, Licensed
Products and to provide Licensed Services in the Territory for the Field. 
 The grant of patent rights herein may be subject to rights
retained by the United States government in accordance with 35 U.S.C. 200-205 and P.L. 96-517, as amended by P.L. 98-620, and subject to the retained right of JHU to make, have made, provide and use for its and The Johns Hopkins Health Systems’
noncommercial research, educational and clinical testing purposes Licensed Product and Licensed Service, including the ability to distribute any biological material covered under Licensed Patent Rights and/or Cell Lines for nonprofit academic
research use to nonprofit entities as is customary in the scientific community. If such biological materials are shared for nonprofit academic research use by a third party, JHU will transfer the biological materials through an agreement that
prohibits commercial use of the transferred material, as well as any progeny or derivatives, including, without limitation, master cell banks and working cell lines. In addition, the United States Government may have acquired a nonexclusive,
nontransferable, irrevocable, paid-up license to practice or have practiced for or on behalf of the United States the inventions described in Licensed Patent Rights throughout the world. The rights granted herein are additionally subject to: the
requirement that any Licensed Product(s) produced for use or sale within the United States shall be substantially manufactured in the United States (unless a waiver under 35 USC § 204 or equivalent is granted by the appropriate United States
government agency), and the right of the United States government to require JHU, or its licensees, including Company, to grant sublicenses to responsible applicants on reasonable terms when necessary to fulfill health or safety needs. 

Company acknowledges that its rights are therefore subject to the foregoing paragraph. 

2.2 Sublicense. Company may sublicense to one or more Sublicensees the rights granted by JHU under this Agreement, and upon
notification to JHU, may extend the right to further sublicense such sublicensed rights subject to the terms and conditions of this Section 2. As a condition to its validity and enforceability, each sublicense agreement shall:
(a) incorporate by reference the terms and conditions of this Agreement, (b) be consistent with the terms, 
  

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 6 

 
conditions and limitations of this Agreement, (c) name JHU as an intended third-party beneficiary of the obligations of Sublicensee without imposition of obligation or liability on the part
of JHU or its Inventors to the Sublicensee, and (d) specifically incorporate Sections 6.2 “Representations by JHU”, 7.1 “Indemnification”, 10.1 “Use of Name”, 10.4 “Product Liability” into the body of the
sublicense agreement, and cause the terms used in therein to have the same meaning as in this Agreement. Company and its Sublicensee(s) shall provide to JHU each proposed sublicense agreement, executed by both Company and Sublicensee. To the extent
that any terms, conditions or limitations of any sublicense agreement are inconsistent with this Agreement, those terms, conditions and limitations are null and void against JHU. 

2.3 Other Third-party Obligations. JHU and Company agree that the rights granted to Company to the Cell Lines and Licensed IP are
subject to the Third-party Obligations specifically identified in Exhibit B and D hereto. 
 2.4 Global Access for Essential
Medicines. This Agreement is subject to the provisions of Exhibit E: GLOBAL ACCESS FOR ESSENTIAL MEDICINES. 
 2.5
Certain Developed IP. If JHU, working independently (including having obtained funding to conduct additional clinical trials), develops new and useful proprietary data, information and/or other intellectual property of any kind relating to the
Licensed IP (“Developed IP”), to the extent that JHU has the right to offer to Company and grant a license to such Developed IP, JHU will disclose the Developed IP to Company and Company agrees to negotiate in good faith with JHU
for the right to use the Developed IP as part of the development and commercialization of Licensed Products 
 ARTICLE 3 

FEES, ROYALTIES, & PAYMENTS 

3.1 License Fee. Company agrees to pay to JHU the license fee set forth in Exhibit F payable in two equal installments as
follows: (i) within [ * ] days following execution of this Agreement and (ii) on the first anniversary of the Effective Date of this Agreement, assuming that the Technology Transfer has been completed to the reasonable satisfaction
of the Company, including, without limitation, the transfer to Company of all Cell Lines Company has reasonably requested. 
 3.2
Milestones License Fees. Company will pay to JHU milestone payments for the Licensed Products developed by Company, its Affiliates, and/or Sublicensees within [ * ] days of achieving the milestones listed in Exhibit F.  

3.3 Minimum Annual Royalties. Company will pay the minimum annual royalties (“Minimum Annual Royalties”) as set forth
in Exhibit F. These Minimum Annual Royalties shall be due within [ * ] days of each anniversary of the Effective Date beginning with the second anniversary of the Effective Date (running royalties accrued and paid to JHU during the
one-year period preceding an anniversary of the relevant Effective Date of this Agreement shall be credited against the Minimum Annual Royalties due on that anniversary date). The amount of all Minimum Annual Royalties paid for any year in excess of
the actual running royalties for such year shall be carried forward and credited against running royalties owed in future years. 
  

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 7 

 3.4 Running Royalties. Company shall pay to JHU a running royalty as set forth in
Exhibit F for each Licensed Product sold and for each Licensed Service provided by Company, its Affiliates and Sublicensee(s) based on Net Sales Revenues and Net Service Revenues for the term of this Agreement. Running royalty payments shall
be made quarterly within [ * ] days of the end of the calendar quarter. The royalty rate shall be reduced by [ * ] in the event there is no Valid Claim of the Licensed Patent Rights in the relevant country covering the Licensed Product
or Licensed Service, as the case may be. 
 3.5 Royalty Offset. In the event that a license to third party intellectual property is
required in order to make, have made, use, have used, import, have imported, offer for sale, sell and have sold a Licensed Product or Licensed Service, the royalty rate shall be abatable by up to [ * ] of the consideration payable to the
third party (i.e. up to [ * ]), provided that the applicable running royalty payable to JHU shall not drop below [ * ] of the running royalty herein calculated before the abatement. 

3.6 One Royalty/One Set of Milestones. In no event shall a Licensed Product or Licensed Service require the payment of two royalties
and/or two sets of milestones by Company under the agreements listed below between the Parties. For clarity, this provision applies to amounts that may be owed by Company hereunder and also under that certain Restated and Amended License Agreement
between JHU and BioSante Pharmaceuticals, Inc., dated as of March 3, 2011, which amends and restates in the entirety that certain License Agreement between JHU and Cell Genesys, Inc. (“Cell Genesys”) dated as of June 15,
2000, as amended by a First Amendment to the License Agreement dated as of March 27, 2008, that certain License Agreement between JHU and Cell Genesys, Inc., dated March 12, 2001, as amended by a First Amendment to the License Agreement
dated as of March 27, 2008, and that certain License Agreement between JHU and Cell Genesys, Inc., dated October 1, 1999, as amended by a First Amendment to the License Agreement dated as of August 30, 2003 (the “JHU
Agreements”). If there is an overlap in payment obligations on a single Licensed Product or Licensed Service under the agreements listed herein, the higher royalty rate or the larger set of milestones (when taken in the aggregate) shall be
the amount payable by Company. In addition, Company shall not be required to pay any milestones already paid prior to the date hereof, or pay milestones twice for a single indication or Licensed Product. JHU has not received any written notice that
would indicate that any milestones are currently due or due and payable under any of the foregoing agreements. 
 3.7 Taxes. All
required non-U.S. withholding related to Licensed Product or Licensed Service sold under this Agreement shall be paid by Company or its Affiliates and shall not be deducted from royalty or other payments due to JHU. If Company is required by law to
withhold non-U.S. taxes, JHU will provide reasonable assistance to Company in its efforts to file such requests as are available under the regulations applicable to the jurisdiction and the taxing agency to eliminate the withholding and/or qualify
the royalty payments made hereunder for reduced rates of income tax withholding under any applicable income tax treaty. 
  

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 8 

 3.8 Sublicense Consideration. In addition to the running royalty as set forth under
Section 3.4, Company shall pay to JHU the agreed percentage set forth below of the cash value of compensation received by Company from a third party in consideration of the grant of a sublicense to such third party of the rights granted by JHU
to Company under this Agreement, including all relevant sublicensing licensing fees, milestone payments, and equity investments in Company or its Affiliate(s) to the extent such investments exceed [ * ] of Fair Market Value (as defined herein
below), provided that the following are specifically excluded from this provision: running royalties, loans, debt financing, equity investments at or below [ * ] of Fair Market Value (as defined herein below), payments or other consideration
or reimbursement for services, research or development, sales and/or marketing activities, and reimbursement for patent costs or milestones payable to JHU under this Agreement (“Sublicense Income”). As documentation, Company will
provide to JHU all relevant information in its possession to the extent reasonably required to confirm amounts payable hereunder in respect of Sublicense Income and which is not the confidential information of a third party, including, but not
limited to, copies of research contracts or other contracts with a performance plan and commensurate budget for research, development, sales and/or marketing activities to be performed by Company, providing that the absence of such information shall
not preclude exclusion from Sublicense Income. 
  

	 	(i)	[ * ] if [ * ]; 

  

	 	(ii)	[ * ] if [ * ]; and 

  

	 	(iii)	For [ * ], [ * ]. 

 In the event that equity in lieu of cash or other consideration is received
by Company in return for granting a sublicense, Company shall either arrange for JHU’s share of such equity to be issued directly to JHU and in the name of “The Johns Hopkins University” or Company shall pay in cash to JHU the Fair
Market Value, as defined below, of JHU’s share of such equity. The term “Fair Market Value” shall mean (i) if the stock is publicly traded, the average price that the stock in question is publicly trading at for [ * ] days
prior to the announcement of the sublicense agreement, or (ii) if the stock is not publicly traded, the value of such stock as determined in its most recent round of financing. 

Notwithstanding anything to the contrary in this Agreement or any JHU Agreement, if (i) Company sublicenses to a third party intellectual property
rights licensed to Company by JHU pursuant to multiple agreements and (ii) in two or more of such agreements with JHU, Company has agreed to pay to JHU a percentage of sublicense income (as defined in each such agreement) that Company
receives from Sublicensees, then the relevant percentages of sublicense income shall not be aggregated and applied to all sublicense income. Instead Company shall calculate the sublicense income payable to JHU under each relevant agreement
based on Company’s reasonable estimate of the value allocable to each set of sublicensed rights, when considered in light of the entire transaction and all other relevant factors. 

3.9 Form of Payment. All payments under this Agreement shall be made in U.S. Dollars by either check or wire transfer. 

 
 [*] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 9 

 3.10 Payment Information. All check payments from Company to JHU shall be sent to: 

Executive Director 
 Johns Hopkins
Technology Transfer 
 The Johns Hopkins University 

100 N. Charles Street, 5th Floor 

Baltimore, MD 21201 
 Attn: JHU
Agreement # A21083 
 or such other addresses which JHU may designate in writing from time to time. Checks are to be made payable to “The Johns Hopkins
University”. Wire transfers may be made through: 
 ACH - currently a domestic system (U.S. payments)  

[ * ]  

Transit/routing/ABA number: [ * ]  

Account number: [ * ]  

Type of account: [ * ]  

CTX format is preferred; CCD+ is also accepted 

Reference: JHU Tech Transfer 

(JHU Agreement A21083) 
 FED
WIRE - Domestic  
 [ * ]  

Transit/routing/ABA number: [ * ]  

Account number: [ * ] 

Type of account: [ * ] 

Reference: JHU Tech Transfer 

(JHU Agreement A21083 
 FED
WIRE - International  
 [ * ]  

SWIFT code: [ * ]  

Account number: [ * ]  

Type of account: [ * ] 

Reference: JHU Tech Transfer 

(JHU Agreement A21083) 
 CHIPS
ABA number: N/A 
 IBAN number: N/A 
  

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 10 

 Company shall provide notice of the date and amount of all ACH payments to JHU’s Financial
Manager by email or telephone. Company shall be responsible for any and all costs associated with wire transfers. 
 3.11 Late
Payments. In the event that any payment due hereunder is not made when due, the payment shall accrue interest beginning on the [ * ] day following the due date thereof, calculated at the annual rate of the sum of (a) [ * ]
plus (b) the prime interest rate quoted by The Wall Street Journal on the date said payment is due, the interest being compounded on the last day of each calendar quarter, provided however, that in no event shall said annual
interest rate exceed the maximum legal interest rate for corporations. Each such payment when made shall be accompanied by all interest so accrued. Said interest and the payment and acceptance thereof shall not negate or waive the right of JHU to
seek any other remedy, legal or equitable, to which it may be entitled because of the delinquency of any payment including, but not limited to termination of this Agreement as set forth in Section 9.2. 

ARTICLE 4 
 PATENT
PROSECUTION, MAINTENANCE, & INFRINGEMENT 
 4.1 Prosecution & Maintenance. 

(a) JHU shall be responsible for the maintenance and prosecution of the TEGVAX patent rights among the Licensed Patent Rights (JHU Ref# C05152
and C11641). JHU shall (a) cause its patent counsel to timely copy Company on all official actions and written correspondence with any patent office, and (b) allow Company a reasonable opportunity to comment and advise JHU. JHU shall
consider and reasonably incorporate all comments and advice. Company shall be responsible for the maintenance and prosecution of the STINGVAX Patent Rights (JHU Ref# C12043). JHU will be notified, in advance, of the filing and prosecution of all
patents and patent applications and have a full opportunity for input, which will be carefully considered by Company. By concurrent written notification to JHU and its patent counsel at least [ * ] days in advance (or later at JHU’s
discretion) of any filing or response deadline, or fee due date, Company may elect not to have a patent application filed in any particular country or not to pay expenses associated with the prosecution or maintaining any patent application or
patent, provided that Company pays for all costs incurred up to JHU’s receipt of such notification. Failure to provide such notification can be considered by JHU to be Company’s authorization to proceed at Company’s expense. Upon such
notification, JHU may file, prosecute, and/or maintain such patent applications or patent at its own expense and for its own benefit, and any rights or license granted hereunder held by Company, Affiliates or Sublicensee(s) relating to the Licensed
Patent Rights which comprise the subject of such patent applications or patent and/or apply to the particular country, shall terminate. 

(b) Company will reimburse JHU for all reasonable documented past costs, and all reasonable future costs associated with preparing, filing,
maintaining and prosecuting the Licensed Patent Rights within the Field. JHU shall provide an invoice of all past patent costs (to the extent not already invoiced and/or paid) after execution of this Agreement. Unreimbursed past patent expenses are
currently estimated at about $[ * ] (this amount does not include estimate for national phase filings for TEGVAX IP (JHU Ref# C11641)). The patent costs shall be due within [ * ] days of receipt of an invoice from JHU. 

 
 [*] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 11 

 4.2 Notification. Each party will notify the other promptly in writing when any
infringement by another is uncovered or suspected. 
 4.3 Patent Enforcement. Company shall have the first right to
enforce and defend any patent within Licensed Patent Rights and in the Field against any infringement or alleged infringement thereof, and shall at all times keep JHU informed as to the status thereof. Before Company commences an action with respect
to any infringement of such patents, Company shall give careful consideration to the views of JHU and to potential effects on the public interest in making its decision whether or not to sue. Thereafter, Company may, at its own expense, institute
suit against any infringer or alleged infringer and control and defend such suit in a manner consistent with the terms and provisions hereof and recover any damages, awards or settlements resulting therefrom subject to Section 4.5. However, no
settlement, consent judgment or other voluntary final disposition of the suit may be entered into without the prior written consent of JHU, which consent shall not be unreasonably withheld. This right to sue for infringement shall not be used in an
arbitrary and capricious manner. JHU shall reasonably cooperate in any such litigation at Company’s expense, including by allowing itself to be joined as a party to such litigation if required for purposes of standing. If Company elects not to
enforce any patent within the Licensed Patent Rights, then it shall so notify JHU in writing within [ * ] days of receiving notice that an infringement exists, and JHU may, in its sole judgment and at its own expense, take steps to enforce
any patent and control, settle, and defend such suit in a manner consistent with the terms and provisions hereof, and recover, for its own account, any damages, awards or settlements resulting therefrom. 

4.4 Patent Invalidity Suit. If a declaratory judgment action is brought naming Company as a defendant and alleging invalidity of any of
the Licensed Patent Rights, JHU may elect to take over the sole defense of the action at its own expense. Company shall cooperate fully with JHU in connection with any such action. 

4.5 Recovery. Any recovery of ordinary (non-punitive) damages by Company under Section 4.3 shall be deemed to reflect loss of
commercial sales, and Company shall pay to JHU an amount calculated by applying the royalty rate defined in Section 3.4 to the non-punitive damages of the recovery net of all costs and expenses associated with each suit or settlement. In the
event a court awards punitive damages to Company in addition to ordinary damages, Company shall pay to JHU [ * ] of such punitive damages awarded in respect of the Licensed IP, net of all reasonable costs and expenses associated with each
suit or settlement. If the cost and expenses exceed the recovery, then [ * ] of the excess shall be credited against royalties payable by Company to JHU hereunder in connection with sales of Licensed Product covered in the Licensed Patent
Rights which are the subject of the infringement suit, in the country of such legal proceedings, provided, however, that any such credit under this Section shall not exceed [ * ] of the royalties otherwise payable to JHU with
regard to sales in the country of such action in any one calendar year, with any excess credit being carried forward to future calendar years. 
  

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 12 

 ARTICLE 5 

OBLIGATIONS OF THE PARTIES 

5.1 Reports. Company shall provide to JHU the following written reports according to the following schedules. 

(a) Company shall provide calendar-quarterly royalty reports, substantially in the form of Exhibit G and due within [ * ] days
of the end of each calendar quarter following the Effective Date of this Agreement beginning after the First Commercial Sale of a Licensed Product or Licensed Service. Royalty Reports shall disclose the amount of Licensed Product(s) and Licensed
Service(s) sold, the total Net Sales Revenues and Net Service Revenues of such Licensed Product(s) and Licensed Service(s), and the running royalties due to JHU as a result of Net Sales Revenues and Net Service Revenues by Company, Affiliates and
Sublicensee(s) thereof. Payment of any such royalties due shall accompany such Royalty Reports. 
 (b) Until Company, an Affiliate or a
Sublicensee(s) has achieved a First Commercial Sale of a Licensed Product or Licensed Service, or received FDA market approval, Company shall provide semiannual Diligence Reports, due within [ * ] days of the end of every June and December
following the Effective Date of this Agreement. These Diligence Reports shall describe Company’s, Affiliate(s)‘s or any Sublicensee(s)‘s technical efforts towards meeting its obligations under the terms of this Agreement. 

(c) Company shall provide Annual Reports within [ * ] days of the end of every December following the Effective Date of this Agreement.
Annual Reports shall include: 
  

	 	(i)	evidence of insurance as required under Section 10.4, or, a statement of why such insurance is not currently required, and 

  

	 	(ii)	identification of all Affiliates which have exercised rights pursuant to Section 2.1, or, a statement that no Affiliate has exercised such rights, and 

 

	 	(iii)	notice of all FDA approvals of any Licensed Product(s) or Licensed Service(s) obtained by Company, Affiliate or Sublicensee, the patent(s) or patent application(s) licensed under this Agreement upon which such product
or service is based, and the commercial name of such product or service, or, in the alternative, a statement that no FDA approvals have been obtained. 

5.2 Records. Company shall make and retain, for a period of [ * ] years following the period of each report required by
Section 5.1, true and accurate records, files and books of account containing all the data reasonably required for the full computation and verification of sales and other information required in Section 5.1. Such books and records shall
be in accordance with generally accepted accounting principles consistently applied. Company shall permit the inspection and copying of such records, files and books of account by JHU or its agents during regular business hours upon [ * ]
business days’ written notice to Company. Such inspection shall not be made more than once each calendar year. All costs of such inspection and copying shall be paid by JHU, provided that if any such inspection shall reveal that an error
has been made in an amount equal to [ * ] or more of that owed for any calendar year, such costs shall 
  

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 13 

 
be borne by Company. As a condition to entering into any such agreement, Company shall include in any agreement with its Affiliates or its Sublicensee(s) which permits such party to make, use,
sell or import the Licensed Product(s) or provide Licensed Service(s), a provision requiring such party to retain records of sales of Licensed Product(s) and records of Licensed Service(s) and other information as required in Section 5.1 and
permit JHU to inspect such records as required by this Section. 
 5.3 Diligence. Company shall use commercially reasonable efforts
to develop and to introduce the Licensed Product(s) and Licensed Service(s) into the commercial market as soon as practicable, consistent with sound and reasonable business practice and judgment; thereafter, until the expiration or termination of
this Agreement, Company shall use commercially reasonable efforts to endeavor to keep Licensed Product(s) and Licensed Service(s) reasonably available to the public. Company shall also exercise commercially reasonable efforts to develop Licensed
Product(s) suitable for different indications within the Field. In addition to the foregoing, Company shall use its commercially reasonable efforts to meet the following milestones. 

 

	 	(a)	[ * ] by [ * ]; 

  

	 	(b)	[ * ] by [ * ]; 

  

	 	(c)	[ * ] by [ * ]; 

  

	 	(d)	[ * ] by [ * ]; 

  

	 	(e)	[ * ] by [ * ]; and 

  

	 	(f)	[ * ] by [ * ]. 

 In the event that unforeseen circumstances prevent the Company
from achieving a diligence milestone, the Company and JHU will agree to discuss alternative commercially reasonable milestones. Company shall provide JHU with notice, as provided hereunder in Section 10.6, within [ * ] days of achieving
each diligence milestone. The foregoing diligence obligations are the only obligations of the Company with respect to GVAX products. 

5.4 Other Products. Beginning on [ * ] and thereafter, if JHU provides the Company in writing with clinical or other compelling
scientific, safety and commercial evidence demonstrating a significant commercial opportunity within the Licensed Field which is not being developed or commercialized by Company, Company shall make reasonable efforts either to provide JHU with a
development plan and start development or attempt to sublicense the particular market or use to a third party. If within [ * ] months of such notification by JHU, Company has not initiated reasonable efforts to finance, develop or sublicense
that particular significant commercial opportunity, JHU may on written notice to the Company terminate this license, but only for the relevant indication, so long as JHU has (i) a bona fide offer to enter into a license for the development of
the indication on terms which are consistent with the terms herein when considered in light of market rates and the breadth and scope of the license, along with a detailed development plan, (ii) JHU and Company have agreed in writing that
development of the indication as planned will not adversely affect current or anticipated development and 
  

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 14 

 
commercialization of Licensed Products and Licensed Services, and (iii) the proposed licensee can demonstrate it has sufficient current funding to fund the development for not less than [
* ] years. In addition, the termination of any indication permitted by this Section shall not be effective until JHU enters into the proposed license and in any event any such license shall be executed by both the parties thereto within six
(6) months of the initiation of negotiation. If the license is not executed prior to the end of such period, then the license shall not be granted by JHU and the termination of the relevant indication shall not be effective. If any license
granted under this provision is terminated for any reason (in whole or in part), written notice of the same will be delivered to Company and the terminated rights shall be automatically restored as part of Company’s rights under this Agreement
as of the date of termination, unless requested otherwise by the Company. For clarity, this Section shall not be applicable if Company reasonably demonstrates to JHU that commercializing such Licensed Product(s) or Licensed Service(s) or granting
such a sublicense in said market or use would have a potentially adverse commercial effect upon development, marketing or sales, or future development, marketing or sales, of the Licensed Product(s). 

5.5 Patent Acknowledgement. Company agrees that all packaging containing individual Licensed Products(s) sold by Company, Affiliates
and Sublicensee(s) of Company will be marked with the number of the applicable patent(s) licensed hereunder in accordance with each country’s patent laws. 

5.6 Technology Transfer. In order to enable Company to exercise the licenses granted herein, JHU, through its inventors, will promptly
disclose and provide to Company all information and materials (including without limitation biological materials) comprising the Licensed IP. The parties acknowledge that this process will be collaborative and will be executed based upon
Company’s needs and the inventors’ reasonable capabilities to complete the transfer. In any event, the Licensed Technology Transfer shall be completed within [ * ] after the Effective Date. Company and JHU shall agree on a
reasonable fee not exceed $[ * ] payable to JHU to fund the costs of the technology transfer including without limitation costs for clerical support. Company shall not be responsible for paying any consideration related to Licensed IP that is
not transferred to Company. JHU shall ship Licensed Technology to the addresses indicated by the Company, at times reasonably acceptable to Company. 

5.7 Cell Line Transfer and Reimbursement. JHU shall deliver to Company not less than the quantity of each Cell Line referenced in
Exhibit B (Section 1) of this Agreement. JHU shall ship the Cell Lines to Company at addresses designated by Company and under physical conditions and at times reasonably requested by the Company. In support of the foregoing, upon transfer of
such Cell Lines, Company shall pay to JHU up to $[ * ], based upon the amounts set forth in Exhibit B (Section 1). In addition, the parties will agree after the Effective Date on a plan for the transfer, security and preservation of
the Cell Lines so as to enable the continued use of all the lines for research by JHU and for research, development and commercialization of products by Company. 

5.8 Additional Cell Lines. At Company’s request, JHU may transfer to Company additional GVAX cell lines existing prior to the
Effective Date of this Agreement and not listed in Exhibit B (“Additional Cell Lines”), including any melanoma lines that become available. Such 
  

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

  
 15 

 
transfer of Additional Cell Lines shall be made only to the extent Additional Cell Lines are unencumbered by any third party rights and subject to availability and reimbursement of agreed and
documented costs of JHU in connection with the transfer and replacement of material. Such transfer shall be accomplished by written amendment to this Agreement with appropriate terms and conditions to be negotiated in good faith between the parties,
provided the parties acknowledge that the terms of this Agreement represent appropriate terms and conditions for similar materials that were negotiated in good faith. The foregoing notwithstanding, JHU is under no obligation to transfer to Company
Additional Cell Lines. 
 ARTICLE 6 

REPRESENTATIONS 
 6.1
Duties of the Parties. JHU is not a commercial organization. It is an institute of research and education. Therefore, JHU has no ability to evaluate the commercial potential of any Licensed Patent Rights or Licensed Product or other license or
rights granted in this Agreement. It is therefore incumbent upon Company to evaluate the rights and products in question, to examine the materials and information provided by JHU, and to determine for itself the validity of any Licensed Patent
Rights, its freedom to operate, and the value of any Licensed Products or Licensed Services or other rights granted. 
 6.2
Representations by JHU. JHU warrants that it has good and marketable title to its interest in the inventions claimed under Licensed Patent Rights with the exception of certain retained rights of the United States Government, which may apply if
any part of the JHU research was funded in whole or in part by the United States Government. To the best of JHTT’s knowledge, JHU has the right to grant the rights, and transfer the materials, to Company that are granted and transferred
hereunder on the terms set forth herein. The parties acknowledge that the transfer of the 3SKBR3 cell line from JHU is not possible until Company receives permission for transfer from Memorial Sloan Kettering. If and when such permission is
obtained, then JHU agrees that it will cooperate in such transfer. JHU does not warrant the validity of any patents or that practice under such patents shall be free of infringement. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, COMPANY,
AFFILIATED COMPANIES AND SUBLICENSEE(S) AGREE THAT THE LICENSED IP ARE PROVIDED “AS IS”, AND THAT JHU MAKES NO REPRESENTATION OR WARRANTY WITH RESPECT TO THE PERFORMANCE OF LICENSED PRODUCT(S) AND LICENSED SERVICE(S) INCLUDING THEIR
SAFETY, EFFECTIVENESS, OR COMMERCIAL VIABILITY. JHU DISCLAIMS ALL WARRANTIES WITH REGARD TO PRODUCT(S) AND SERVICE(S) LICENSED UNDER THIS AGREEMENT, INCLUDING, BUT NOT LIMITED TO, ALL WARRANTIES, EXPRESSED OR IMPLIED, OF MERCHANTABILITY AND FITNESS
FOR ANY PARTICULAR PURPOSE. NOTWITHSTANDING ANY OTHER PROVISION OF THIS AGREEMENT, JHU ADDITIONALLY DISCLAIMS ALL OBLIGATIONS AND LIABILITIES ON THE PART OF JHU AND INVENTORS, FOR DAMAGES, INCLUDING, BUT NOT LIMITED TO, DIRECT, INDIRECT, SPECIAL,
AND CONSEQUENTIAL DAMAGES, ATTORNEYS’ AND EXPERTS’ FEES, AND COURT COSTS (EVEN IF JHU HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, FEES OR COSTS), ARISING OUT OF OR IN CONNECTION WITH THE MANUFACTURE, USE, OR SALE OF THE PRODUCT(S)
AND SERVICE(S) LICENSED UNDER THIS AGREEMENT. 
  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 

  
 16 

 
COMPANY, AFFILIATED COMPANIES AND SUBLICENSEE(S) ASSUME ALL RESPONSIBILITY AND LIABILITY FOR LOSS OR DAMAGE CAUSED BY A PRODUCT AND/OR SERVICE MANUFACTURED, USED, OR SOLD BY COMPANY, ITS
SUBLICENSEE(S) AND AFFILIATED COMPANIES WHICH IS A LICENSED PRODUCT(S) OR LICENSED SERVICE(S) AS DEFINED IN THIS AGREEMENT. 
 ARTICLE 7

 INDEMNIFICATION 

7.1 Indemnification. Company, Affiliates and Sublicensee(s) shall indemnify, defend with counsel reasonably acceptable to JHU and hold
JHU, The Johns Hopkins Health Systems, their present and former trustees, officers, inventors of Licensed IP, agents, faculty, employees and students (“Indemnitee”) harmless as against any judgments, fees, expenses, or other costs
arising from or incidental to any product liability or other lawsuit, claim, demand or other action brought as a consequence of the practice of said inventions by any of the foregoing entities, whether or not JHU or said inventors, either jointly or
severally, is named as a party defendant in any such lawsuit and whether or not JHU or the inventors are alleged to be negligent or otherwise responsible for any injuries to persons or property. Practice of the inventions covered by Licensed
Product(s) and Licensed Service(s), by an Affiliate or an agent or a Sublicensee(s) or a third party on behalf of or for the account of Company or by a third party who purchases Licensed Product(s) and Licensed Service(s) from Company, shall be
considered Company’s practice of said inventions for purposes of this Section. The obligation of Company to defend and indemnify as set out in this Section shall survive the termination of this Agreement, shall continue even after assignment of
rights and responsibilities to an Affiliate or Sublicensee, and shall not be limited by any other limitation of liability elsewhere in this Agreement. 

7.2 Indemnity Procedure. Any Indemnitee seeking indemnification under this Agreement shall promptly notify Company of any claim,
demand, action or other proceeding for which such Indemnitee intends to claim such indemnification. Company shall have the right to participate in consideration by the Indemnitee of the financial aspect only of the settlement of any claim, demand,
action or other proceeding, but Company may not unreasonably withhold or delay approval of the financial aspect of any settlement. The failure of the Indemnitee to deliver notice to Company within a reasonable time after actual notice of any such
claim or demand, or the commencement of any such action or other proceeding, if materially prejudicial to the ability to defend such claim, demand, action or other proceeding, shall relieve Company of any liability under this Section 7 with
respect thereto. Each Indemnitee, its employees and agents, shall reasonably cooperate with Company and its legal representatives in the investigation of any claim, demand, action or other proceeding covered by this Section 7 at the expense of
Company. 
 ARTICLE 8 

CONFIDENTIALITY 
 8.1
Confidentiality. If necessary, the parties will exchange information, which they consider to be confidential. The recipient of such information agrees to accept the disclosure of said information which is marked as confidential at the time it is
sent to the recipient, and to employ all reasonable efforts to maintain the information secret and confidential, such efforts to 
  

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

  
 17 

 
be no less than the degree of care employed by the recipient to preserve and safeguard its own confidential information. The information shall not be disclosed or revealed to anyone except
employees of the recipient who have a need to know the information and who have entered into a secrecy agreement with the recipient under which such employees are required to maintain confidential the proprietary information of the recipient and
such employees shall be advised by the recipient of the confidential nature of the information and that the information shall be treated accordingly. 
 The
obligations of this Section 8.1 shall also apply to Affiliates and/or Sublicensee(s) provided such information by Company. JHU’s, Company’s, Affiliates, and Sublicensee(s)‘s obligations under this Section 8.1 shall extend
until [ * ] years after the termination of this Agreement. 
 8.2 Exceptions. The recipient’s obligations under
Section 8.1 shall not extend to any part of the information: 
 (a) that can be demonstrated to have been in the public domain or
publicly known and readily available to the trade or the public prior to the date of the disclosure; or 
 (b) that can be demonstrated,
from written records to have been in the recipient’s possession or readily available to the recipient from another source not under obligation of secrecy to the disclosing party prior to the disclosure; or 

(c) that becomes part of the public domain or publicly known by publication or otherwise, not due to any unauthorized act by the recipient; or

 (d) that is demonstrated from written records to have been developed by or for the receiving party without reference to confidential
information disclosed by the disclosing party. 
 (e) that is required to be disclosed by law, government regulation or court order. 

8.3 Right to Publish. JHU may publish manuscripts, abstracts or the like describing the Licensed Patent Rights and inventions contained
therein provided confidential information of Company as defined in Section 8.1, is not included or without first obtaining approval from Company to include such confidential information. Otherwise, JHU and the Inventors shall be free to publish
manuscripts and abstracts or the like directed to the work done at JHU related to the Licensed Technology without prior approval. 

ARTICLE 9 

TERM & TERMINATION 

9.1 Term. Unless earlier terminated as permitted herein, the term of this Agreement shall commence on the Effective Date and shall
continue for thirty (30) years after the First Commercial Sale of a Licensed Product, provided the term may be extended for multiple additional ten (10) year periods upon the mutual agreement of Company and JHU, such agreement not to be
unreasonably withheld by JHU. In connection with any such extension or 
  
 [*] =
Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 

  
 18 

 
consideration thereof, the following shall apply: (i) JHU agrees that it will not ask for any additional or increased consideration and (ii) so long as a Licensed Product or Licensed
Service is being marketing and sold commercially and Company is not in material breach of the Agreement, then JHU shall not object to such extension of term. 

9.2 Termination by Either Party. This Agreement may be terminated by either party if the other party (a) files or has filed
against it a petition under the Bankruptcy Act, makes an assignment for the benefit of creditors, has a receiver appointed for it or a substantial part of its assets, or otherwise takes advantage of any statute or law designed for relief of debtors
and it is not dismissed within ninety (90) days thereafter, or (b) breaches any of its material obligations hereunder, if, following the giving of notice by the terminating party of the breach and its intent to terminate and stating the
grounds therefor, the breaching party shall not have cured the breach within sixty (60) days (thirty (30) days for nonpayment and amounts due and payable). In no event, however, shall such notice or intention to terminate be deemed to
waive any rights to damages or any other remedy which the party giving notice of breach may have as a consequence of such failure or breach. Accrued obligations, such as payment of owed royalties, are not affected by termination. 

9.3 Termination by Company. Company may terminate this Agreement and the license granted herein, for any reason, upon giving JHU ninety
(90) days’ written notice. Company may remove any Licensed IP from the license on thirty (30) days written notice to JHU. 

9.4 Obligations and Duties upon Termination. If this Agreement is terminated other than for the uncured material breach of JHU, both
parties shall be released from all obligations and duties imposed or assumed hereunder to the extent so terminated, except as expressly provided to the contrary in this Agreement. Upon termination, both parties shall cease any further use of the
confidential information disclosed to the receiving party by the other party. Termination of this Agreement, for whatever reason, shall not affect any accrued obligations including without limitation any obligation of either party to make any
payments for which it is liable prior to or upon such termination. Termination shall not affect JHU’s right to recover unpaid royalties, fees, reimbursement for patent expenses, or other forms of financial compensation incurred prior to
termination. Upon termination Company shall submit a final royalty report to JHU and any royalty payments, fees, unreimbursed patent expenses and other financial compensation due JHU shall become immediately payable and all Cell Lines and Licensed
Technology shall be returned to JHU. Furthermore, upon termination of this Agreement, all rights in and to the Licensed IP shall revert immediately to JHU at no cost to JHU. Upon termination of this Agreement, any Sublicensee(s) shall become a
direct licensee of JHU, provided that JHU’s obligations to Sublicensee(s) are no greater than JHU’s obligations to Company under this Agreement. Company shall provide written notice of such to each Sublicensee(s) with a copy of such notice
provided to JHU. 
 ARTICLE 10 

MISCELLANEOUS 
 10.1 Use
of Name. Company, Affiliates and Sublicensee(s) shall not use the name of The Johns Hopkins University or The Johns Hopkins Health System or any of its constituent 
  

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

  
 19 

 
parts, such as the Johns Hopkins Hospital or any contraction thereof or the name of Inventors in any advertising, promotional, sales literature or fundraising documents without prior written
consent from an authorized representative of JHU. Company, Affiliates and Sublicensee(s) shall allow at least seven (7) business days’ notice of any proposed public disclosure for JHU’s review and comment or to provide written
consent. 
 10.2 No Partnership. Nothing in this Agreement shall be construed to create any agency, employment, partnership, joint
venture or similar relationship between the parties other than that of a licensor/licensee. Neither party shall have any right or authority whatsoever to incur any liability or obligation (express or implied) or otherwise act in any manner in the
name or on the behalf of the other, or to make any promise, warranty or representation binding on the other. 
 10.3 Notice of Claim.
Each party shall give the other or its representative immediate notice of any suit or action filed, or prompt notice of any claim made, against them arising out of the performance of this Agreement or arising out of the practice of the inventions
licensed hereunder. 
 10.4 Product Liability. Prior to initial human testing or First Commercial Sale of any Licensed Product(s) or
Licensed Service(s) as the case may be in any particular country, Company shall establish and maintain, for each country in which Company or an Affiliate, or Sublicencee(s) shall test or sell Licensed Product(s) and Licensed Service(s), product
liability, or other appropriate insurance coverage, in the minimum amount of (i) for Phase 2 Clinical Trials or earlier, Five Million Dollars per occurrence ($5,000,000) and Five Million Dollars ($5,000,000) in the aggregate, and (ii) for
Phase 3 Clinical Trials and after, Seven Million Five Hundred Thousand Dollars ($7,500,000) per occurrence (which will increase to $10M as of commercialization of a Licensed Product) and Ten Million Dollars ($10,000,000) in the aggregate, and will
annually present evidence to JHU that such coverage is being maintained. Upon JHU’s request, Company will furnish JHU with a Certificate of Insurance of each product liability insurance policy obtained. JHU shall be listed as an additional
insured in Company’s said insurance policies. If such product liability insurance is underwritten on a ‘claims-made’ basis, Company agrees that any change in underwriters during the term of this Agreement will require the purchase of
‘prior acts’ coverage to ensure that coverage will be continuous throughout the term of this Agreement. A change in underwriters will not be made unless claims arising prior to the date of the change during the term of this Agreement are
covered. 
 10.5 Governing Law. This Agreement shall be construed, and legal relations between the parties hereto shall be
determined, in accordance with the laws of the State of New York applicable to contracts solely executed and wholly to be performed within the State of New York without giving effect to the principles of conflicts of laws. Any disputes between the
parties to this Agreement shall be brought in the state or federal courts of Maryland. Both parties agree to waive their right to a jury trial. 

10.6 Notice. All notices or communication required or permitted to be given by either party hereunder shall be deemed sufficiently
given if mailed by registered mail or certified mail, return receipt requested, or sent by overnight courier, such as Federal Express, to the other party 
  

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

  
 20 

 
at its respective address set forth below or to such other address as one party shall give notice of to the other from time to time hereunder. Mailed notices shall be deemed to be received on the
third business day following the date of mailing. Notices sent by overnight courier shall be deemed received the following business day. 
  

					
	 If to Company:
		 Aduro BioTech
 626 Bancroft Way, Suite 3C

Berkeley, CA 94710-2225
 Attn: Chief Executive Officer
		
			
	 If to JHU:
		 Executive Director
 Johns Hopkins Technology
Transfer
 The Johns Hopkins University
 100 N. Charles
Street
 5th Floor

Baltimore, MD 21201
 Attn: Agreement #A21083
		

 10.7 Compliance All Laws. In all activities undertaken pursuant to this Agreement, both JHU and Company
covenant and agree that each will comply with such Federal, state and local laws and statutes, as may be in effect at the time of performance and all valid rules, regulations and orders thereof regulating such activities. 

10.8 Successors and Assigns. Neither this Agreement nor any of the rights or obligations created herein, except for the right to
receive any remuneration hereunder, may be assigned by either party, in whole or in part, without the prior written consent of the other party, except that either party shall be free to assign this Agreement in connection with any sale of
substantially all of its assets related to this Agreement without the consent of the others; provided that: (a) any such assignee shall agree in writing to be bound by the terms and conditions of this Agreement; and (b) the assigning party
shall notify the other party of any such assignment. This Agreement shall bind and inure to the benefit of the successors and permitted assigns of the parties hereto. 

10.9 No Waivers; Severability. No waiver of any breach of this Agreement shall constitute a waiver of any other breach of the same or
other provision of this Agreement, and no waiver shall be effective unless made in writing. Any provision hereof prohibited by or unenforceable under any applicable law of any jurisdiction shall as to such jurisdiction be deemed ineffective and
deleted herefrom without affecting any other provision of this Agreement. It is the desire of the parties hereto that this Agreement be enforced to the maximum extent permitted by law, and should any provision contained herein be held by any
governmental agency or court of competent jurisdiction to be void, illegal and unenforceable, the parties shall negotiate in good faith for a substitute term or provision which carries out the original intent of the parties. 

10.10 Entire Agreement; Amendment. Company and JHU acknowledge that they have read this entire Agreement and that this Agreement,
including the attached Exhibits and, to the 
  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 

  
 21 

 
extent relevant, the JHU Agreements and the side letter between the parties dated the date hereof, constitutes the entire understanding and contract between the parties hereto and supersedes any
and all prior or contemporaneous oral or written communications with respect to the subject matter hereof, all of which communications are merged herein. It is expressly understood and agreed that (i) there being no expectations to the contrary
between the parties hereto, no usage of trade, verbal agreement or another regular practice or method dealing within any industry or between the parties hereto shall be used to modify, interpret, supplement or alter in any manner the express terms
of this Agreement; and (ii) this Agreement shall not be modified, amended or in any way altered except by an instrument in writing signed by both of the parties hereto. 

10.11 Delays or Omissions. Except as expressly provided herein, no delay or omission to exercise any right, power or remedy accruing to
any party hereto, shall impair any such right, power or remedy to such party nor shall it be construed to be a waiver of any such breach or default, or an acquiescence therein, or in any similar breach or default be deemed a waiver of any other
breach or default theretofore or thereafter occurring. Any waiver, permit, consent or approval of any kind or character on the part of any party of any breach or default under this Agreement, or any waiver on the part of any party of any provisions
or conditions of this Agreement, must be in writing and shall be effective only to the extent specifically set forth in such writing. All remedies either under this Agreement or by law or otherwise afforded to any party, shall be cumulative and not
alternative. 
 10.12 Force Majeure. If either party fails to fulfill its obligations hereunder (other than an obligation for the
payment of money), when such failure is due to an act of God, or other circumstances beyond its reasonable control, including but not limited to fire, flood, civil commotion, riot, war (declared and undeclared), revolution, or embargoes, then said
failure shall be excused for the duration of such event and for such a time thereafter as is reasonable to enable the parties to resume performance under this Agreement; provided, however, that in no event shall such time extend for a period of more
than one hundred eighty (180) days. 
 10.13 Further Assurances. Each party shall, at any time, and from time to time, prior to
or after the Effective Date of this Agreement, at reasonable request of the other party, execute and deliver to the other such instruments and documents and shall take such actions as may be required to more effectively carry out the terms of this
Agreement. 
 10.14 Survival. All representations, warranties, covenants and agreements made herein and which by their express terms
or by implication are to be performed after the execution and/or termination hereof, or are prospective in nature, shall survive such execution and/or termination, as the case may be. This shall include Sections 3 (to the extent accrued monies are
unpaid) and Articles 7, 8, 9.4, and 10 (as applicable). 
 10.15 No Third-Party Beneficiaries. Nothing in this Agreement shall be
construed as giving any person, firm, corporation or other entity, other than the parties hereto and their successors and permitted assigns, any right, remedy or claim under or in respect of this Agreement or any provision hereof. 

 
 [*] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

  
 22 

 10.16 Headings. Article headings are for convenient reference and not a part of this
Agreement. All Exhibits are incorporated herein by this reference. 
 10.17 Counterparts. This Agreement may be executed in
counterparts, each of which shall be deemed an original and all of which when taken together shall be deemed but one instrument. 

[Signatures on following page.] 
  

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

  
 23 

 IN WITNESS WHEREOF, this Agreement shall take effect as of the Effective Date when it has been
executed below by the duly authorized representatives of the parties. 
  

					
	THE JOHNS HOPKINS UNIVERSITY				ADURO BIOTECH, INC.
			
	 /s/ Wesley D. Blakeslee, J.D
				 /s/ Stephen T. Isaacs

	 Wesley D. Blakeslee, J.D., CLP
 Executive
Director
 Johns Hopkins Technology Transfer
				 Stephen T. Isaacs
 President and
CEO

 EXHIBIT A. LICENSED PATENT RIGHTS 

EXHIBIT B. CELL LINES AND ENCUMBRANCES 
 EXHIBIT C. CERTAIN
LICENSED TECHNOLOGY 
 EXHIBIT D. ALL THIRD-PARTY OBLIGATIONS FOR LICENSED TECHNOLOGY 

EXHIBIT E. GLOBAL ACCESS FOR ESSENTIAL MEDICINES 
 EXHIBIT F.
LICENSE FEES AND ROYALTIES 
 EXIHIBIT G. QUARTERLY SALES & ROYALTY REPORT 

 
 [*] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

  
 24 

 EXHIBIT A 

LICENSED PATENT RIGHTS 
 [ * ] 

 
 [*] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 EXHIBIT B 

CELL LINES AND ENCUMBRANCES 
  

	1.	CELL LINES 

 [ * ] 

 

	 	2.	CELL LINE DESCRIPTION AND ENCUMBRANCES 

 [ * ] 

 
 [*] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 EXHIBIT C 

CERTAIN LICENSED TECHNOLOGY1 

[ * ] 
  

	1 	All Attachments referenced herein have been provided to Company under separate cover. 

  

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 EXHIBIT D 

ALL THIRD-PARTY OBLIGATIONS FOR LICENSED TECHNOLOGY 

[ * ] 
  

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 EXHIBIT E 

GLOBAL ACCESS FOR ESSENTIAL MEDICINES 

Subject to any requirements of relevant laws, rules, regulations, guidelines and standards of all relevant jurisdictions, as well as all
obligations and retained rights applicable to the Licensed Patent Rights, including without limitation those set forth in Section 2.1 and 2.2 of this Agreement, the following terms shall be deemed to be a part of this Agreement. For clarity,
this provision does not require Company to license, or permit JHU to license on its behalf, any of its information or intellectual property or products to any third party. 
  

	1)	DEFINITIONS 

 “GAVI Country” shall mean any country listed as eligible to receive
support from the GAVI Alliance (as such list may be amended from time to time, provided it shall not include any major market countries or Brazil, Russia, India or China.) 

“Humanitarian Purpose” shall mean practice of the Licensed Patent Rights by a Qualified Humanitarian Organization to manufacture Licensed
Products in GAVI Countries for which no reasonable alternatives exist in such GAVI Countries, for the sole and express purposes of distribution of such Licensed Products in one or more GAVI Countries solely in the Public Charitable Market for end
use by low-income end users in such GAVI Country at actual cost (with no profit) or no cost to the end user or the end user’s governmental entities. 

“Non-GAVI Country” shall mean any country that is not a GAVI Country. 

“Qualified Humanitarian Organization” shall mean any not-for-profit organization that addresses the public health needs of underserved
populations solely on a not-for-profit basis. For clarity, Qualified Humanitarian Organizations do not include governmental organizations, foundations, generic biological or pharmaceutical companies, and foundations or non-for-profit organizations
that are formed or established for the benefit of, or which partner with, or support, any for-profit or governmental entity. 
 “Public Charitable
Market” shall mean markets that, due to economic circumstance and public health emergency cannot afford to purchase Licensed Products at the cost for which such Licensed Products are available in their country. The Public Charitable Market
shall not include product tender markets (such as PAHO or UNICEF) or private markets. 
  

	2)	Limited Retained Rights. 

 Should Company have no plans to commercialize Licensed Product
in GAVI Countries, subject to all other terms and requirements herein, JHU has the right to grant a nonexclusive license to the Licensed Patent Rights (but not jointly-owned Licensed Patent Rights) to a Qualified Humanitarian Organization solely for
Humanitarian Purposes in the Public Charitable Market, but only as needed to produce products for end use in GAVI Countries. Such a license shall not be granted until (i) Company has developed a Licensed Product or Licensed Service that is
proven to be capable of scalable 
  
 [*] = Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
manufacture that permits distribution (including all relevant logistical considerations) and sale of the Licensed Product or Licensed Service in GAVI Countries at locally-affordable prices (with
a reasonable profit and while reasonably protecting other markets) and with consistent quality, and (b) after the Company has a bona fide offer to do so with a viable manufacturing and commercial partner proven to be capable of effectively
working in the GAVI Country in compliance with all relevant laws, rules, regulations, guidelines and standards, and the Company refuses such opportunity without a reasonable explanation as to the reasons why the same would not be commercially
reasonable. The third-party license shall terminate automatically if (i) any Licensed Product (whether or not in development) is made available in any Non-GAVI Country directly or indirectly by the licensee, or if any other intellectual
property of Company or JHU is infringed or misappropriated by the making, using, selling or importation of any relevant products, or (ii) a compulsory license is granted in such jurisdiction. Prior to entering any licenses with third parties
pursuant to this provision, JHU will give at least twelve (12) months’ prior written notice to Company of JHU’s intent to consider or enter into such a license or manufacture and distribute in such market on its own, which notice will
include all pertinent information concerning the opportunity, and Company shall have the first right to negotiate a license directly with the organization. 
  

	3)	Expansion into New Markets. 

 The Company shall consider how it might effectively and
efficiently manufacture and sell Licensed Product and Licensed Services into GAVI Countries and whether such plans are reasonable and feasible in light of the logistical, quality, manufacturing, economic and scientific challenges related thereto, as
well as the demonstrated need therefor in light of medical alternatives and other relevant factors. In connection therewith, JHU agrees to consider reasonable requests of Company for a commensurate reduction of royalty and sublicensing fees in
circumstances where Company demonstrates to the satisfaction of JHU that Licensed Products are or will be made available in such developing nations at reduced cost, as compared to the U.S. market and taking into account a reasonable profit. 

 
 [*] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 EXHIBIT F 

LICENSE FEES AND ROYALTIES 

1. The License Fee due pursuant to Section 3.1 is Two Hundred Fifty Thousand U.S. Dollars ($250,000). 

2. The Milestone License fees due pursuant to Section 3.2 shall be paid only once for a TEGVAX-based Licensed Product, once for a
STINGVAX-based Licensed Product, and once for one other Licensed Product that does not fall into one of the two (2) foregoing categories: 
  

	 	(i)	[ * ] upon [ * ]; 

  

	 	(ii)	[ * ] upon [ * ]; 

  

	 	(iii)	[ * ] upon [ * ]; 

  

	 	(iv)	[ * ] upon [ * ]; and 

  

	 	(v)	[ * ] upon [ * ]. 

 Milestone License Fees are not payable on Licensed Services.

 As STINGVAX is jointly-owned by JHU and Company, milestones will be reduced for STINGVAX by [ * ] for milestones (i) -
(iii) above. 
 3. The Minimum Annual Royalties due pursuant to Section 3.3 are: 

[ * ] 
 4. The running royalty rate
payable under Section 3.4 is equal to [ * ], subject to any offsets or reductions including without limitation those in Sections 3.4 and 3.5, provided that in no event shall the royalty payable hereunder be reduced below [ * ].

  
 [*] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 EXHIBIT G 

QUARTERLY SALES & ROYALTY REPORT 

FOR LICENSE AGREEMENT BETWEEN 

                    ADURO BIOTECH
INC.                     

AND 
 THE JOHNS HOPKINS
UNIVERSITY 
 DATED
                     
 JHU Reference
Number(s)                     ,
                     
 PERIOD: From
             To              

TOTAL ROYALTIES DUE FOR THIS PERIOD $             

 

													
	 PRODUCT

       ID
	  	 PRODUCT

NAME
	  	 *JHU

REF #
	  	
1st
COMMERCIAL
SALE DATE
	  	 TOTAL

NET
 SALES/

SERVICES
	  	 ROYALTY

RATE
	  	 AMOUNT

DUE

		  		  		  		  		  		  	
		  		  		  		  		  		  	
		  		  		  		  		  		  	
		  		  		  		  		  		  	
		  		  		  		  		  		  	
		  		  		  		  		  		  	

  

	*	Please provide the JHU Reference Number or Patent Reference 

 This report format is to be used to
report quarterly royalty statements to JHU. It should be placed on Company letterhead and accompany any royalty payments due for the reporting period. After the first sale on which royalties accrue, his report shall be submitted even if no sales are
reported. 
  
 [*] = Certain confidential information contained in this document,
marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.EX-10.25

 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and
filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 Exhibit
10.25 
 RESTATED AND AMENDED LICENSE AGREEMENT 

This Restated and Amended License Agreement (“Restated and Amended Agreement”, JHU Ref. No. A18558) is made as of the EFFECTIVE DATE
by and between The Johns Hopkins University, a corporation of the State of Maryland, having a principal place of business at 3400 N. Charles St., Baltimore, MD 21218 (hereinafter referred to as “JHU”) and BioSante Pharmaceuticals,
Inc, a Delaware corporation (hereinafter referred to as “Company”), having an address at 111 Barclay Boulevard, Suite 280, Lincolnshire, IL 60069. 

WITNESSETH: 
 WHEREAS, Cell
Genesys, Inc. and JHU entered into a License Agreement effective June 15, 2000, and as amended on March 27, 2008 (JHU Ref. Nos. C09769, C03007 and C03096; JHU Agreement No. A00552) (“LICENSE AGREEMENT”); 

WHEREAS, Company acquired Cell Genesys, Inc on October 14, 2009 and is the successor-in-interest to the LICENSE AGREEMENT; 

WHEREAS, Company and JHU wish to restate and amend certain provisions of the LICENSE AGREEMENT; 

 NOW, THEREFORE, in consideration of the foregoing premises and the following mutual covenants,
and other good and valuable consideration the receipt of which is hereby acknowledged, and intending to be legally bound hereby, the parties agree as follows: 

ARTICLE 1 - DEFINITIONS 

1.1 “AFFILIATED COMPANY” or “AFFILIATED COMPANIES” shall mean any corporation, company, partnership, joint venture or
other entity which controls, is controlled by or is under common control with the Company. For purposes of this Paragraph 1.1, control shall mean the direct or indirect ownership of at least fifty percent (50%) (or, the maximum ownership
percentage allowed in the applicable jurisdiction, if lower) of the shares of the subject entity entitled to vote in the election of directors (or, in the case of an entity that is a corporation, for the election of the corresponding managing
authority). 
 1.2 “BIOLOGICAL MATERIALS” shall mean all cells, cell lines and other materials provided to Company under this
Agreement and covered by the PATENT RIGHTS. 
 1.3 “EFFECTIVE DATE” of this Restated and Amended Agreement shall mean the date the
last party hereto has executed this Agreement. 
 1.4 “[ * ] PATENT” shall mean that invention entitled [ * ], U.S.
Patent Application Serial No. [ * ] filed on [ * ], which was conducted during the course of research conducted by [ * ], and licensed to [ * ] under the license agreement effective [ * ]. 

1.5 “LICENSED FIELD” shall mean all applications (including all allogeneic and autologous forms of immunotherapy). 

1.6 “LICENSED MELANOMA PRODUCT(S)” shall mean any material, composition, drug, cell preparation, or other product (a) the
manufacture, use or sale of which would constitute, but for the license granted to Company pursuant to this Agreement, an infringement of a claim of the JHU/NIH MELANOMA PATENT RIGHTS 

 
 [*] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
(infringement shall include, but is not limited to, direct, contributory, or inducement to infringe), is covered by a pending claim of JHU/NIH MELANOMA PATENT RIGHTS or incorporates a BIOLOGICAL
MATERIAL, and (b) has received FDA or other regulatory approval to be marketed, sold, or used (or is marketed or sold) in the treatment of melanoma. 

1.7 “LICENSED NON-MELANOMA PRODUCT(S)” shall mean any material, composition, drug, cell preparation, or other product other than a
LICENSED MELANOMA PRODUCT. 
 1.8 “LICENSED PRODUCT(S)” shall mean LICENSED MELANOMA PRODUCT(S) and/or LICENSED NON-MELANOMA
PRODUCT(S). 
 1.9 “LICENSED MELANOMA SERVICE(S)” means the commercial performance on behalf of a third party of any method
including therapeutic service or the manufacture of any product or the use of any product or composition which (a) would constitute, but for the license granted to Company pursuant to this Agreement, an infringement of a claim of the JHU/NIH
MELANOMA PATENT RIGHTS, (infringement shall include, but not be limited to, direct, contributory or inducement to infringe) or is covered by a pending claim of JHU/NIH MELANOMA PATENT RIGHTS or incorporates a BIOLOGICAL MATERIAL, and (b) has
received FDA or other regulatory approval to be marketed, sold, or used (or is marketed or sold) in the treatment of melanoma. 
 1.10
“LICENSED NON-MELANOMA SERVICE(S)” means any commercial performance on behalf of a third party of any method including therapeutic service or the manufacture of any product or the use of any product or composition other than a LICENSED
MELANOMA SERVICE. 
  
 [*] = Certain confidential information contained in this
document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 1.11 “LICENSED SERVICE(S)” shall mean LICENSED MELANOMA SERVICE(S) and/or LICENSED
NON-MELANOMA SERVICE(S). 
 1.12 “NET SALES”, subject to Paragraph 4.10 below, shall mean gross sales revenues and fees billed by
Company, AFFILIATED COMPANY and SUBLICENSEES from the sale of LICENSED PRODUCT(S) less (i) trade discounts allowed, refunds, returns and recalls, (ii) sales taxes and other governmental charges and duties (including value added tax)
actually paid, and (iii) provisions for uncollectible accounts determined in accordance with generally accepted accounting principles, consistently applied to all products of the selling party. Except as set forth in Paragraph 4.5, in the event
that Company, AFFILIATED COMPANY, or SUBLICENSEE sells a LICENSED PRODUCT(S) in combination with another drug as part of a combination product (as such drug is defined in the marketing application to the FDA), the NET SALES for purposes of royalty
payments shall be calculated by multiplying the NET SALES of that combination by the fraction A/A+B, where A is Company’s then gross selling price of the LICENSED PRODUCT sold separately and B is the lowest, then-current fair market gross
selling price of the other drug sold separately, provided that no deduction shall be made for costs for drugs not defined in the marketing application, provided further that in no event shall the NET SALES be reduced below an amount equal to the
product of the number of combinations sold multiplied by Company’s then selling price for the LICENSED PRODUCT(S) if sold on a stand-alone basis, and provided further that any drug that is not an FDA-approved, therapeutically active,
stand-alone product (even if noted in the marketing application) in its own right shall be disregarded in respect to this Paragraph 1.12. 
  

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 1.13 “NET SERVICE REVENUES”, subject to Paragraph 4.10 below, shall mean actual
billings for the performance of LICENSED SERVICE(S) less (i) sales and/or use taxes and other governmental charges and duties (including value added tax) imposed upon and with specific reference to the LICENSED SERVICE and (ii) provisions
for uncollectible accounts determined in accordance with generally accepted accounting principles, consistently applied to all products/services of the selling party. 

1.14 “PATENT RIGHTS” shall mean the JHU/WHITEHEAD PATENTS, the JHU ALLOGENEIC PARACRINE PATENT APPLICATIONS, or the JHU/NIH MELANOMA
PATENT APPLICATION, as each are further described on Exhibit “A” attached hereto, and the inventions disclosed and claimed therein, and all continuations, divisions, continuation in part applications (to the extent the new subject matter
reads on claims in the originally filed U.S. utility application), substitutions, extensions, reexaminations, and reissues based thereof, and any corresponding foreign patent applications, and any patents, patents of addition, or other equivalent
foreign patent rights issuing, granted or registered thereon. 
 1.15 “SUBLICENSEE” shall mean any third party (other than an
AFFILIATED COMPANY) to whom Company has granted a sublicense under this Restated and Amended Agreement. 
 1.16 “VALID CLAIM”
shall mean a claim of an issued and unexpired patent or a claim of a patent application within PATENT RIGHTS that has been pending for less than [ * ] years from its filing date. 

ARTICLE 2 - GRANTS 
 2.1
Subject to the terms and conditions of this Agreement (particularly Paragraph 2.2 below), JHU hereby grants to Company a license under the PATENT RIGHTS to 
  

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
make, have made, use, import and sell the LICENSED PRODUCT(S) and to provide the LICENSED SERVICE(S) in the United States and worldwide under the PATENT RIGHTS in the LICENSED FIELD. This Grant
shall apply to the Company and any AFFILIATED COMPANY, except that any AFFILIATED COMPANY shall not have the right to sublicense others as set forth in Paragraph 2.3 below. If any AFFILIATED COMPANY exercises rights under this Agreement, such
AFFILIATED COMPANY shall be bound by all terms and conditions of this Agreement, including but not limited to indemnity and insurance provisions and royalty payments, which shall apply to the exercise of the rights, to the same extent as would apply
had this Agreement been directly between JHU and the AFFILIATED COMPANY. In addition, Company shall remain fully liable to JHU for all acts and obligations of AFFILIATED COMPANY such that acts of the AFFILIATED COMPANY shall be considered acts of
the Company. 
 2.2 The license granted in respect to the JHU/WHITEHEAD PATENTS shall be subject to the rights of The Whitehead Institute
for Biological Research to exploit and enforce its co-interest (and to authorize others to do so, including, without limitation, granting and authorizing other licenses to grant and authorize sublicenses). The license granted in respect to the
JHU/NIH MELANOMA PATENT RIGHTS shall be subject to: (a) the right of the Public Health Service (“PHS”) to require JHU, or its licensees (including Company), to grant sublicenses to responsible applicants, on reasonable terms, when
necessary to fulfill health or safety needs; (b) the requirement that any LICENSED PRODUCT(S) that practice(s) any claim under the JHU/NIH MELANOMA PATENT RIGHTS and is/are produced for use and sale within the United States shall be
substantially manufactured in the United States; (c) the rights of the United States 
  

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
government as set forth under 37 C.F.R. Part 401, and (d) the Public Health Service Interinstitutional Agreement between JHU and the PHS dated 17 January 1997 and attached hereto as
Exhibit B “”. A letter providing written approval from the NIH for the granting of an exclusive license to Company by JHU for JHU/NIH MELANOMA PATENT APPLICATION is attached hereto as Exhibit C”‘. The license granted pursuant to
this Agreement shall be subject to: (a) the rights retained by the United States government in accordance with P.L. 96-517, as amended by P.L. 98-620; and (b) the rights retained by JHU to make, have made, provide and use for its and The
Johns Hopkins Health Systems’ non-profit purposes the LICENSED PRODUCT(S) and the LICENSED SERVICE(S). 
 2.3 Except as provided
herein, Company may grant and authorize sublicenses to others under this Agreement and shall provide a copy of each such sublicense agreement to JHU promptly after it is executed provided that Company shall have the right to redact such portions of
such sublicense agreement not applicable to obligations of Company or such SUBLICENSEE under this Agreement, and further provided that such agreement shall be considered confidential information under Paragraph 5.3. Each sublicense shall be
consistent with the terms of this Agreement. As a condition to its validity and enforceability, each sublicense agreement shall: (a) incorporate by reference the terms and conditions of this Agreement, (b) be consistent with the terms,
conditions and limitations of this Agreement, (c) prohibit SUBLICENSEE’s further sublicense of the rights delivered hereunder, (d) name JHU as an intended third party beneficiary of the obligations of SUBLICENSEE without imposition of
obligation or liability on the part of JHU or its Inventors to the SUBLICENSEE, (e) specifically 
  

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
incorporate Paragraphs 9.6, 9.7, 9.8 and 9.9 into the body of the sublicense agreement, and cause the terms used in therein to have the same meaning as in this Agreement. To the extent that any
terms, conditions or limitations of any sublicense agreement are inconsistent with this Agreement, those terms, conditions and limitations are null and void against JHU. 

ARTICLE 3 - PATENT INFRINGEMENT 

3.1 Each party will notify the other promptly in writing when any infringement of PATENT RIGHTS by another is uncovered or suspected. 

3.2 Subject to Paragraph 3.4 below, Company shall have the first right (through itself or others) to enforce any patent within the PATENT
RIGHTS against any infringement or alleged infringement thereof and/or to defend any declaratory judgment action with respect thereto, and shall at all times keep JHU informed as to the status thereof. Company may, in sole judgment and at its own
expense, institute suit against any such infringer or alleged infringer and control, settle, and defend such suit in a manner consistent with the terms and provisions hereof and recover, for its account, any damages, awards or settlements resulting
therefrom, subject to Paragraph 3.5. This right to sue for infringement shall not be used in an arbitrary or capricious manner. JHU shall reasonably cooperate in any such litigation at Company’s expense, including without limitation, by joining
as a party plaintiff and executing such documents as Company may request. 
 3.3 If Company elects not to enforce any patent within the
PATENT RIGHTS, then it shall so notify JHU in writing within [ * ] months of receiving notice that an infringement 
  

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
exists, and JHU may, in its sole judgment and at its own expense, take steps to enforce any patent and control, settle, and defend such suit in a manner consistent with the terms and provisions
hereof, and recover, for its own account, any damages, awards or settlements resulting therefrom. 
 3.4 JHU shall have the first right to
enforce any patent rights granted under the JHU/NIH MELANOMA PATENT APPLICATION. Company shall only have the right to enforce patent rights granted under the JHU/NIH MELANOMA PATENT APPLICATION if both JHU and PHS elect not to enforce such rights,
whether jointly or separately. In no such event shall Company take any action to compel PHS to initiate or join in any suit for patent infringement, except to the extent possible under the JHU/PHS agreement. Should PHS be made a party to any suit as
a result of Company action, Company shall pay all costs, fees, and expenses incurred by PHS, including all costs, fees, and expense incurred by opposing any such action. PHS shall have the right (but not the obligation) to join in any suit brought
by the Company. 
 3.5 Any recovery by Company of compensatory (i.e., non-punitive damages net of legal fees and out-of-pocket costs of the
action) under Paragraph 3.2 or 3.4 shall be deemed to reflect loss of commercial sales, and Company shall pay to JHU the applicable royalty rate on infringing NET SALES. Infringing NET SALES shall be determined by and calculated from the amount of
infringing sales on which the award of compensatory damages is based. With respect to any recovery of punitive damages with respect to royalty-bearing products, Company shall pay to JHU an amount equal to [ * ] thereof. 

 
 [*] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 ARTICLE 4 - PAYMENTS. ROYALTIES. AND RESEARCH SUPPORT 

4.1 Company will reimburse JHU for the reasonable costs of preparing, filing, maintaining and prosecuting the PATENT RIGHTS prior to the
effective date (except that the Company shall be directly responsible for all future costs associated with preparing, filing, maintaining and prosecuting the JHU/WHITEHEAD PATENTS). In accordance with Paragraph 5.1 below, Company will reimburse JHU,
within [ * ] days of the receipt of an invoice from JHU, for all costs associated with the preparation, filing, maintenance, and prosecution of PATENT RIGHTS incurred by JHU subsequent to the EFFECTIVE DATE of this Agreement. 

4.2 The Company shall pay to JHU a [ * ] annual license fee due within [ * ] days of each anniversary of the EFFECTIVE DATE of
the Restated and Amended Agreement. [ * ] Dollars ($[ * ]) of such fee shall be allocated to the JHU/WHITEHEAD PATENT RIGHTS and [ * ] Dollars ($[ * ]) shall be allocated to the JHU ALLOGENEIC PARACRINE PATENT RIGHTS and
the JHU/NIH MELANOMA PATENT RIGHTS. Such fees are nonrefundable and shall not be credited against royalties or other fees. 
 4.3 Throughout
the term of this Agreement, Company shall pay to JHU an annual royalty for each LICENSED PRODUCT(S) sold and each LICENSED SERVICE(S) provided worldwide by the Company, AFFILIATED COMPANIES and SUBLICENSEES so long as such LICENSED PRODUCT(S) or
LICENSED SERVICE(S) is covered by a VALID CLAIM under any PATENT RIGHTS. Annual royalties shall be paid quarterly as provided in Paragraph 4.8. 

4.4 The Company shall pay to JHU a running royalty in an amount equal to [ * ] of the NET SALES and [ * ] of NET SERVICE
REVENUES of such LICENSED PRODUCT(S) or LICENSED SERVICE(S). 
  
 [*] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 In the event that JHU receives any royalties in respect to the JHU/NIH MELANOMA PATENTS, JHU shall pay the Public
Health Service any sums due under the Public Health Service Interinstitutional Agreement between JHU and PHS. 
 4.5 Royalties owed pursuant
to Paragraph 4.4 shall not be subject to deductions or reductions because of third party patents or other royalties and shall be determined upon the price of the entire final LICENSED PRODUCT(S) or LICENSED SERVICE(S). Notwithstanding anything in
the aforegoing to the contrary, the determination of the royalty for the sale of any LICENSED PRODUCT shall exclude any other product if such other product is administered as part of a combination treatment regimen with a LICENSED PRODUCT and such
other product has been separately approved by the FDA or an equivalent agency. 
 4.6 Sublicense Consideration. In addition to the running
royalty as set forth under Paragraph 4.4, Company shall pay to JHU [ * ] of the cash value of any and all consideration received for sublicenses under this Agreement. This sublicense consideration shall be due, without the need for invoice
from JHU, within [ * ] days of Company’s receipt of a payment. Such consideration shall mean consideration of any kind received by the Company or AFFILIATED COMPANIES from a SUBLICENSEE(S) for the grant of a sublicense under this
Agreement, such as upfront fees or milestone fees and including any premium paid by the SUBLICENSEE(S) over Fair Market Value for stock of the Company or an AFFILIATED COMPANY in consideration for such sublicense. However, not included in such
sublicense consideration are amounts paid to the Company or an AFFILIATED COMPANY by the SUBLICENSEE(S) for (i) running royalties on LICENSED PRODUCT(S) and LICENSED SERVICE(S), and (ii) product development, research work, clinical studies
and regulatory 
  
 [*] = Certain confidential information contained in this
document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
approvals to be performed by or for the Company or AFFILIATED COMPANIES (including third parties on their behalf) subsequent to the EFFECTIVE DATE of this Restated and Amended Agreement, each
pursuant to [ * ], the [ * ]. The term “Fair Market Value” shall mean the average price that the stock in question is publicly trading at for [ * ] days prior to the announcement of its purchase by the SUBLICENSEE(S)
or if the stock is not publicly traded, the value of such stock as determined by the most recent private financing through a financial investor (an entity whose sole interest in the Company or AFFILIATED COMPANY is financial) of the Company or
AFFILIATED COMPANY that issued the shares. 
 4.7 The Company shall pay to JHU the following milestone payments (not creditable against
earned royalties) within [ * ] days of the events indicated below: 
  

	 	(A)	For JHU/WHITEHEAD PATENT: [ * ] 

  

	 	(B)	For JHU ALLOGENEIC PARACRINE PATENT APPLICATION: 

  

	 	(1)	[ * ]: 

 [ * ] 

 

	 	(2)	[ * ]: 

 [ * ] 

 

	 	(3)	[ * ]: 

 [ * ] 

 
 [*] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	 	(4)	[ * ]: 

 [ * ] 

Milestones (2) through (4) above, however, shall be paid only for the first three (3) LICENSED NON-MELANOMA PRODUCTS or LICENSED
NON-MELANOMA SERVICES covered by a claim under the JHU ALLOGENEIC PARACRINE PATENT RIGHTS. 
  

	 	(C)	For JHU/NIH MELANOMA PATENT APPLICATION: 

  

	 	(1)	[ * ]: 

 [ * ] 

 

	 	(2)	[ * ]: 

 [ * ] 

 

	 	(3)	[ * ]: 

 [ * ] 

 

	 	(4)	[ * ]: 

 [ * ] 

Milestones (2) through (4) above, however, shall be paid only for the first LICENSED MELANOMA PRODUCT or LICENSED MELANOMA SERVICE
covered by a claim under the JHU/NIH MELANOMA PATENT APPLICATION. Milestones (2) and (3) above are understood to occur and be paid prior to FDA or other regulatory approval for marketing. 

 
 [*] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 4.8 Up until the time of the Company receiving FDA approval for a LICENSED PRODUCT or LICENSED
SERVICE, the Company shall provide to JHU within [ * ] days of the end of each December after the EFFECTIVE DATE, an annual written report to JHU of the amount of LICENSED PRODUCTS sold and LICENSED SERVICES sold, the total NET SALES and NET
SERVICE REVENUES of such LICENSED PRODUCTS and LICENSED SERVICES, and the running royalties due to JHU as a result of NET SALES and NET SERVICE REVENUES by Company, AFFILIATED COMPANIES and SUBLICENSEES thereof. Payment of any such royalties due
shall accompany such report. Upon receipt of FDA approval for a LICENSED PRODUCT or LICENSED SERVICE, the Company shall provide thereafter a written report within [ * ] days after each March, June, September and December including the amount
of approved LICENSED PRODUCT sold and approved LICENSED SERVICE provided, the total NET SALES and NET SERVICE REVENUES of such LICENSED PRODUCT and LICENSED SERVICE, and the running royalties due to JHU. Until the Company, an AFFILIATED COMPANY or a
SUBLICENSEE has initiated a clinical trial and has achieved a first commercial sale of a LICENSED MELANOMA PRODUCT or LICENSED MELANOMA SERVICE and a LICENSED NON-MELANOMA PRODUCT or LICENSED NON-MELANOMA SERVICE (and has received FDA market
approval for such LICENSED PRODUCT(S) or LICENSED SERVICES), a report shall be submitted at the end of every December after the EFFECTIVE DATE and will include a full written report describing the Company’s, AFFILIATED COMPANIES and
SUBLICENSEE’S technical efforts towards meeting the milestones in Article 6. 
  

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 4.9 The Company shall make and retain, for a period of [ * ] years following the period of
each report required by Paragraph 4.8, true and accurate records, files and books of account containing all the data reasonably required for the full computation and verification of sales and other information required in Paragraph 4.8. Such books
and records shall be in accordance with generally accepted accounting principles consistently applied. The Company shall permit the inspection and copying of such records, files and books of account by JHU or its agents during regular business hours
upon [ * ] business days’ written notice to the Company. Such inspection shall not be made more than once each calendar year. All costs of such inspection and copying shall be paid by JHU, provided that if any such inspection shall
reveal that an error has been made in the amount equal to [ * ] or more of such payment, such costs shall be borne by the Company. The Company shall include in any agreement with its AFFILIATED COMPANIES or any SUBLICENSEE which permits such
party to make, use or sell the LICENSED PRODUCT(S) or provide the LICENSED SERVICE(S), a provision requiring such party to retain records of sales of such LICENSED PRODUCT(S) and records of LICENSED SERVICE(S) and other information as required in
Paragraph 4.8 and permit JHU to inspect such records as required by this Paragraph 4.9. Notwithstanding the foregoing, if Company does not have the right to grant to JHU the right to audit any SUBLICENSEES’ books and records, Company shall
obtain for itself such right and, at JHU’s request, Company shall exercise such audit right with respect to such SUBLICENSEES; provided, that (i) Company shall provide the results of such audit for inspection by JHU pursuant to this
Paragraph 4.9, and (ii) Company shall use an independent auditor reasonably acceptable to JHU to conduct such audit. In such event, Company shall obtain for itself such right to audit at least once per calendar year. 

 
 [*] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 4.10 In order to insure JHU the full royalty payments contemplated hereunder, the Company agrees
that in the event any LICENSED PRODUCT shall be sold or any LICENSED SERVICE shall be provided to an AFFILIATED COMPANY or SUBLICENSEE or to a corporation, firm or association with which Company shall have any agreement, understanding or arrangement
with respect to consideration (such as, among other things, an option to purchase stock or actual stock ownership, or an arrangement involving division of profits or special rebates or allowances) the royalties to be paid hereunder for such LICENSED
PRODUCT(S) shall be based upon the greater of: 1) the net selling price at which the purchaser of LICENSED PRODUCT(S) or LICENSED SERVICE(S) resells such product to the end user, 2) the NET SERVICE REVENUE received from using the LICENSED PRODUCT(S)
or LICENSED SERVICE(S) in providing a service, 3) the fair market value of the LICENSED PRODUCT(S) or LICENSED SERVICE(S), or 4) the net selling price of LICENSED PRODUCT(S) or LICENSED SERVICE(S) paid by the purchaser. 

4.11 Form of Payment. All payments under this Agreement shall be made in U.S. Dollars. Checks are to be made payable to “The Johns
Hopkins University” and sent to 
 Director 

Technology Transfer 

The Johns Hopkins University 

100 N. Charles Street 

5th Floor 

Baltimore, MD 21201 

Attn: A18558 
  

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 or such other addressee which JHU may designate in writing from time to time. Checks are to be
made payable to “The Johns Hopkins University”. Wire transfers may be made through: 
 [ * ] 

Transit/Routing/ABA number: [ * ]  

SWIFT code: [ * ]  

CHIPS ABA number: [ * ]  

Account Number: [ * ]  

Type of account: [ * ] 

or ACH  
 [ * ]

 Transit/routing/ABA number: [ * ]  

Account number: [ * ]  

Type of account:[ * ] 

Reference: JHU Tech Transfer 

(JHU Ref. No.: A18558) 
 Attn:
Financial Manager 
 Company shall be responsible for any and all costs associated with wire transfers. 

ARTICLE 5 - PROSECUTION OF PATENT RIGHTS AND CONFIDENTIAL INFORMATION 

5.1 Except for the JHU/WHITEHEAD PATENT, for which Company shall hereafter be directly responsible for the prosecution and maintenance of
such, JHU, at the Company’s expense, shall file, prosecute and maintain all patents and patent applications specified under PATENT RIGHTS upon authorization of the Company and the Company shall be licensed thereunder. Title to all patents and
patent applications shall reside in JHU. JHU shall have full and complete control over all patent matters in connection therewith except that Company shall be copied directly on all patent 

 
 [*] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
correspondence, provided copies of all correspondence received from any patent office and provided drafts of any papers or applications to be filed at least [ * ] weeks prior to patent
office submission for Company comment and Company comments shall be considered and reasonably incorporated. The Company will provide payment authorization to JHU at least [ * ] before an action is due, provided that the Company has received
timely notice of such action from JHU. Failure to provide authorization can be considered by JHU as a Company decision not to authorize an action. In any country where the Company elects not to have a patent application filed or to pay expenses
associated with filing, prosecuting, or maintaining a patent application or patent (or if such is the case with the JHU/WHITEHEAD PATENT), JHU may file, prosecute, and/or maintain a patent application or patent at its own expense and for its own
exclusive benefit and the Company thereafter shall not be licensed under such, patent or patent application. 
 5.2 Company agrees that all
packaging containing individual LICENSED PRODUCT(S) sold by Company, AFFILIATED COMPANIES and SUBLICENSEES and all materials in respect to LICENSED SERVICE(S) provided by company, AFFILIATED COMPANIES and SUBLICENSEES of Company will be marked with
the number of the applicable patent(s) licensed hereunder in accordance with each country’s patent laws. 
 5.3 If necessary, the
parties will exchange information which they consider to be confidential. The recipient of such information agrees to accept the disclosure of said information which is marked as confidential at the time it is sent to the recipient (collectively,
“Confidential Information”), and to employ all reasonable efforts to maintain the Confidential Information as secret and confidential, such efforts to be no less than the 

 
 [*] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
degree of care employed by the recipient to preserve and safeguard its own confidential information. The Confidential Information of the other party shall not be disclosed or revealed to anyone
except employees or agents of the recipient who have a need to know the information and who have entered into a secrecy agreement with the recipient under which such employees are required to maintain the confidentiality of information such as the
Confidential Information and such employees or agents shall be advised by the recipient of the confidential nature of the Confidential Information and that the Confidential Information shall be treated accordingly. The recipient’s
obligations under this Paragraph 5.3 shall not extend to any part of the Confidential Information: 
 a. that can be
demonstrated to have been in the public domain or publicly known and readily available to the trade or the public prior to the date of the disclosure; or 

b. that can be demonstrated, from written records to have been in the recipient’s possession or readily available to the
recipient from another source not under obligation of secrecy to the disclosing party prior to the disclosure: or 
 c. that
becomes part of the public domain or publicly known by publication or otherwise, not due to any unauthorized act by the recipient; or 

d. that is demonstrated from written records to have been developed by or for the receiving party without reference to
Confidential Information disclosed by the disclosing party; or 
 e. that is required to be disclosed by law, government
regulation, or court order. 
  
 [*] = Certain confidential information contained in
this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 The obligations of this Paragraph 5.3 shall also apply to AFFILIATED COMPANIES and/or SUBLICENSEES. JHU’s,
Company’s, AFFILIATED COMPANIES’, and SUBLICENSEES’ obligations under this Paragraph 5.3 shall continue until [ * ] years after the termination of this Agreement. Notwithstanding the foregoing, the receiving party may use or
disclose Confidential Information of the disclosing party to the extent necessary to exercise its rights hereunder (including commercialization and/or sublicensing of the PATENT RIGHTS) or fulfill its obligations and/or duties hereunder and in
prosecuting or defending litigation and/or submitting information to tax or other governmental authorities; provided, that if the receiving party is required by law to make any public disclosures of Confidential Information of the disclosing party,
to the extent it may legally do so, it will give reasonable advance notice to the disclosing party of such disclosure and will use its reasonable efforts to secure confidential treatment of Confidential Information prior to its disclosure (whether
through protective orders or otherwise). 
 ARTICLE 6 - TERM AND COMMERCIAL EFFORTS 

6.1 This Agreement shall expire in each country on the date of expiration of the last to expire patent included within PATENT RIGHTS in that
country or if no patents issue then twenty (20) years from the EFFECTIVE DATE of this Agreement. 
 6.2 Company shall use reasonable
commercial efforts to develop and commercialize the LICENSED PRODUCT(S) and LICENSED SERVICE(S) using good scientific judgment. Specifically, with respect to the development of an allogeneic cell line for a particular tumor type, Company shall meet
the milestones set forth in Paragraphs 6.3 through 6.7. 
  
 [*] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 6.3 Company may give written notice to JHU requesting to undertake commercially reasonable
efforts to file either a corporate IND or a corporate drug master file with respect to any tumor types or JHU may give written notice to Company that JHU is requesting that Company then agree to undertake commercially reasonable efforts to file
either a corporate IND or a corporate drug master file with respect to tumor types. (In the event that any Company-sponsored research in the JHU laboratories of Dr. Drew Pardoll or Dr. Elizabeth Jaffee addresses any of these tumor
types, the definition of “tumor types” may then be defined in greater detail in a subsequent agreement to specify a product based on a cell line developed by either researcher.) 

6.4 In reply to written notice by Company or by JHU, JHU shall provide, to the extent known by JHU, a detailed, final clinical data report and
reports from all prior clinical trials and other materials for the tumor type justifying the commencement of commercially reasonable efforts by Company to file either a corporate IND or a corporate drug master file. If JHU is conducting such
clinical research and developing an allogeneic cell line, JHU will provide Company with a clinical progress report at least [ * ] months prior to the submission of the final clinical report. Such data may be auditable by Company or its
designee upon request. 
 6.5 Upon receipt of written notice by JHU or Company, Company shall have [ * ] months to evaluate and
decide whether to commence commercially reasonable efforts itself or through a third party to file a corporate IND or a corporate drug master file within [ * ] months after Company’s decision to proceed. If Company decides 

 
 [*] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
to commence such an effort, it will notify JHU in writing of its intent and shall deliver to JHU an appropriate clinical plan and timeline. The parties agree that if manufacturing or other
technical issues beyond Company’s control prevent Company from so filing, Company shall be given additional time equal to the length of the delay. If Company does not agree to commence such commercially reasonable efforts, Company upon request
of JHU will enter into good faith negotiations with any reputable third party identified by JHU for an exclusive license to JHU’s interest in the intellectual property for the LICENSED PRODUCTS OR LICENSED SERVICES. Company will use
commercially reasonable efforts to consummate such a license within [ * ] months of JHU notifying Company of the name of a reputable third party that has expressed definitive interest in obtaining such an exclusive license. The terms of
such a license shall be commercially reasonable and shall consider the contributions of Company and/or its partners in developing the GVAX® platform. In the event: (a) the Company has not
agreed to commence commercially reasonable efforts itself or through a third party to file a corporate IND or a corporate drug master file; and (b) JHU has identified a reputable third party which is interested in an exclusive license as
described above; and (c) the Company has not consummated such a license within [ * ] months of JHU’s notifying the Company of such third party’s interest then except if the third party does not agree to commercially reasonable
terms, in such event, the license granted hereunder shall be terminated as of the last day of such [ * ] month period. 
  

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 6.6 If the Parties so agree to commence efforts to file a corporate IND or a corporate drug
master file, JHU shall then license exclusively to Company the allogeneic cell line regarding the particular tumor type. In such event, Company shall: (i) reimburse JHU for the cost of development and testing the particular cell line in excess
of the funding provided to Dr. Jaffee (pursuant to paragraph 7.1) up to a maximum of [ * ] per cell line; (ii) pay JHU’s customary licensing processing fee of [ * ] and an annual fee of [ * ]; and
(iii) reimburse JHU for all reasonable patent costs. Said reimbursements and payments shall be the sole economic consideration for any such license. 

6.7 If Company agrees to commence efforts to file a corporate IND or corporate drug master file for the particular tumor type subject to
JHU’s notice, it is understood that Company will use reasonable commercial efforts to: 
  

	 	-	Develop a scaleable manufacturing process 

  

	 	-	Conduct an appropriate “bridging study” to confirm that the scaleable manufacturing process yields a product comparable to that evaluated in the preliminary clinical studies performed by JHU 

 

	 	-	Conduct a Phase II clinical trial 

  

	 	-	Conduct an end of Phase II meeting with FDA 

  

	 	-	Conduct Phase Ill clinical trials consistent with FDA 

 Upon request, Company shall provide JHU with periodic
progress reports showing Company’s reasonable commercial efforts to achieve the above milestones at a frequency not to exceed every [ * ] months. 
  

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 6.8 Company shall not be required to act upon JHU’s written notice if Company has commenced
or can provide written documentation that it has plans to commence the development of a product similar to the one for JHU’s intended tumor type. 

6.9 JHU, through JHU inventors of PATENT RIGHTS, shall provide Company periodic updates on clinical trials for products covered under the
PATENT RIGHTS and under development by the JHU inventors of the PATENT RIGHTS in order to evaluate for potential clinical development by Company as contemplated hereunder. Company will not publicly disclose any information contained in said updates,
unless approved by JHU in accordance with Section 9.6. 
 ARTICLE 7 - CLINICAL TRIALS 

7.1 Company shall consider in good faith JHU’s participation as a clinical site for future Phase I and Phase II clinical trials for LICENSED PRODUCTS in
accordance with a customary Clinical Trials Agreement. Such consideration shall include, but not be limited to, consideration as a site for renal cancer trials. Company shall consider the following factors when determining whether JHU shall serve as
the clinical sites for such studies: (i) resources available at JHU for trial; (ii) personnel available at JHU for trial; and (iii) the patient referral base at JHU that is available for trial. In the event Company chooses not to use
JHU as the site for such studies Company shall notify JHU of such decision in writing and give a detailed explanation concerning the reason JHU was not chosen for such clinical trial. JHU shall have [ * ] days to respond to such notice. If
JHU responds in writing within such [ * ] day period Company shall reasonably and in good faith consider JHU’s response before making its final determination. 
  

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 ARTICLE 8 - BREACH AND TERMINATION 

8.1 Upon breach or default of any of the terms and conditions of this Agreement, the defaulting party shall be given written notice of such
default in writing and a period of sixty (60) days after receipt of such notice to correct the default or breach. If the default or breach is not corrected within said sixty (60) day period, the party not in default shall have the right to
terminate this Agreement. Failure by Company to use commercially reasonable efforts to make any payments hereunder, including patent reimbursements, shall be considered a breach. 

8.2 Company may terminate this Agreement and the license granted herein, for any reason, upon giving JHU sixty (60) days written notice.

 8.3 Termination shall not affect JHU’s right to recover unpaid royalties or fees or reimbursement for patent expenses incurred prior
to termination. Upon termination all rights in and to the licensed technology shall revert to JHU at no cost to JHU. In the event this Agreement is terminated for any reason, Company shall provide JHU with a written inventory of all LICENSED
PRODUCTS and LICENSED SERVICES that Company and its AFFILIATED COMPANIES have the right to sell or otherwise dispose of, all subject to the payment to JHU of royalties pursuant to Article 4 hereof. Upon termination of this Agreement by either party
for any reason, any sublicense granted by the Company hereunder shall survive, provided that (i) the SUBLICENSEE is not in breach of its sublicense agreement, (ii) the SUBLICENSEE agrees to be bound directly to JHU as a licensor under the
terms and conditions of the sublicense agreement, and (iii) JHU’s obligations to SUBLICENSEE(S) are no greater than JHU’s obligations to Company under this Agreement. 

 
 [*] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 ARTICLE 9 - MISCELLANEOUS 

9.1 All notices pertaining to this Agreement shall be in writing and sent certified mail, return receipt requested, or by courier, to the
parties at the following addresses or such other address as such party shall have furnished in writing to the other party in accordance with this Paragraph 9.1: 
  

			
	FOR JHU:		The Johns Hopkins University
			Johns Hopkins Technology Transfer
			100 N. Charles Street, 5th Floor
			Baltimore, Maryland 21201
			Notices to be sent to: The Director.
			Agreement Ref. No.: A18558
		
	FOR COMPANY:		BioSante Pharmaceuticals, Inc
			111 Barclay Boulevard, Suite 280
			Lincolnshire, Illinois 60069
			Notices to be sent to: President & CEO.

 9.2 All written progress reports, and any other related correspondence shall be in writing and sent to: 

The Johns Hopkins University 

Johns Hopkins Technology Transfer 

100 N. Charles Street, 5th Floor 

Baltimore, Maryland 21201 

Notices to be sent to: The Director. 

Agreement Ref. No.: A18558 
 or such other
addressee which JHU may designate in writing from time to time. 
  
 [*] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 9.3 This Agreement binding upon and shall inure to the benefit of both parties, their successors
and assignees and shall not be assignable without the written consent of the other party, which consent shall not be unreasonably withheld, except that the Company shall have the right to assign this Agreement to another party without the consent of
JHU in the case of the sale or transfer by the Company of all, or substantially all, of its assets or business relating to the LICENSED PRODUCT or LICENSED SERVICE, to that party by sale, merger, operation of law, or otherwise. 

9.4 In the event that any one or more of the provisions of this Agreement should for any reason be held by any court or authority having
jurisdiction over this Agreement, or over any of the parties hereto to be invalid, illegal or unenforceable, such provision or provisions shall be reformed to approximate as nearly as possible the intent of the parties, and if unreformable, shall be
divisible and deleted in such jurisdictions; elsewhere, this Agreement shall not be affected. 
 9.5 The construction, performance, and
execution of this Agreement shall be governed by the laws of the State of Maryland. Any disputes between the parties to the Agreement shall be brought in the state or federal courts of Maryland. Both parties agree to waive their right to a jury
trial. 
 9.6 The Company shall not use the name of THE JOHNS HOPKINS UNIVERSITY or THE JOHNS HOPKINS HEALTH SYSTEM or any of its
constituent parts, such as the Johns Hopkins Hospital or any contraction thereof or the name of Inventors of PATENT RIGHTS in any press releases, advertising, promotional, sales literature or fundraising documents without prior written consent from
an officer of JHU. Company shall allow at least seven (7) business days notice of any proposed public disclosure for JHU’s review and comment or to provide written consent. 

 
 [*] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 9.7 JHU warrants that it has good and marketable title to its interest in the inventions claimed
under PATENT RIGHTS with the exception of certain retained rights of the United States government and others as stated herein and that it has the right and authority to enter into this Agreement and grant the licenses contemplated hereunder. JHU
does not warrant the validity of any patents or that practice under such patents shall be free of infringement. EXCEPT AS EXPRESSLY SET FORTH IN THIS PARAGRAPH 9.7, COMPANY, AFFILIATED COMPANIES AND SUBLICENSEES AGREE AND ACKNOWLEDGE THAT THE PATENT
RIGHTS ARE PROVIDED “AS IS”, AND THAT JHU MAKES NO REPRESENTATION OR WARRANTY WITH RESPECT TO THE PERFORMANCE OF LICENSED PRODUCT(S) AND LICENSED SERVICE(S) INCLUDING THEIR SAFETY, EFFECTIVENESS, OR COMMERCIAL VIABILITY, JHU DISCLAIMS ALL
WARRANTIES WITH REGARD TO PRODUCT(S) AND SERVICE(S) LICENSED UNDER THIS AGREEMENT, INCLUDING, BUT NOT LIMITED TO, ALL WARRANTIES, EXPRESS OR IMPLIED, OF MERCHANTABILITY AND FITNESS FOR ANY PARTICULAR PURPOSE. NOTWITHSTANDING ANY OTHER PROVISION OF
THIS AGREEMENT, JHU ADDITIONALLY DISCLAIMS ALL OBLIGATIONS AND LIABILITIES ON THE PART OF JHU AND INVENTORS, FOR DAMAGES, INCLUDING, BUT NOT LIMITED TO, DIRECT, INDIRECT, SPECIAL, AND CONSEQUENTIAL DAMAGES, ATTORNEYS’ AND EXPERTS’ FEES,
AND COURT COSTS (EVEN IF JHU HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, FEES OR COSTS), ARISING OUT OF OR IN CONNECTION WITH THE MANUFACTURE, USE, OR SALE OF THE PRODUCT(S) AND SERVICE(S) LICENSED UNDER THIS AGREEMENT. COMPANY, AFFILIATED
COMPANIES AND SUBLICENSEES ASSUME 
  
 [*] = Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
ALL RESPONSIBILITY AND LIABILITY FOR LOSS OR DAMAGE CAUSED BY A PRODUCT AND SERVICE MANUFACTURED, USED, OR SOLD BY COMPANY, ITS SUBLICENSEES AND AFFILIATED COMPANIES WHICH IS A LICENSED PRODUCT
OR LICENSED SERVICE AS DEFINED IN THIS AGREEMENT. 
 9.8 JHU and the Inventors of LICENSED PRODUCT(S) and LICENSED SERVICE(S) will not,
under the provisions of this Agreement or otherwise, have control over the manner in which Company or its AFFILIATED COMPANIES or its SUBLICENSEES or those operating for its account or third parties who purchase LICENSED PRODUCT(S) or LICENSED
SERVICE(S) from any of the foregoing entities, practice the inventions of LICENSED PRODUCT(S) and LICENSED SERVICE(S). The Company, AFFILIATED COMPANIES and SUBLICENSEE(S) shall indemnify, defend, with counsel reasonably acceptable to JHU, and hold
JHU, The Johns Hopkins Health Systems, their present and former trustees, officers, Inventors of PATENT RIGHTS, agents, faculty, employees and student (collectively, “lndemnitees”) harmless as against any judgments, fees, expenses, or
other costs arising from or incidental to any product liability or other lawsuit, claim, demand or other action brought as a consequence of the practice of said inventions by any of the foregoing entities, whether or not JHU or said Inventors,
either jointly or severally, is named as a party defendant in any such lawsuit and whether or not JHU or the Inventors are alleged to be negligent or otherwise responsible for any injuries to persons or property; provided, that any party that
intends to claim indemnification under this Paragraph 9.8 shall: (i) promptly notify Company in writing of any claim with respect to which the party intends to claim such 

 
 [*] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
indemnification, (ii) give Company sole control of the defense and/or settlement thereof (provided that there shall be no settlement without the indemnified party’s consent, which shall
not be unreasonably withheld or delayed), and (iii) provide Company, at Company’s expense, with reasonable assistance and full information with respect to such claim. As used in the previous sentence, “former” means an Indemnitee
that is not associated with JHU at the time of the defense by Company but was associated with JHU (e.g., was a trustee of JHU) as of the EFFECTIVE DATE. Practice of the inventions covered by LICENSED PRODUCT(S) and LICENSED SERVICE(S), by an
AFFILIATED COMPANY or an agent or a SUBLICENSEE or a third party on behalf of or for the account of the Company or by a third party who purchases LICENSED PRODUCT(S) and LICENSED SERVICE(S) from the Company, shall be considered the Company’s
practice of said inventions for purposes of this Paragraph 9.8. Notwithstanding the foregoing, Company shall have no obligations for any claim, fee, expense or otherwise if the party seeking indemnification, prior to Company assuming such
defense, makes any settlement, damaging admission or other communication regarding the same without the prior written consent of Company, which consent shall not be unreasonably withheld. The obligation of Company to defend and indemnify as set
out in this Paragraph shall survive the termination of this Agreement, shall continue even after assignment of rights and responsibilities to an affiliate, and shall not be limited by any other limitation of liability elsewhere in this Agreement.

 9.9 Prior to initial human testing or first commercial sale by Company, an AFFILIATED COMPANY, or SUBLICENSEE of any LICENSED PRODUCT(S)
or commercial performance of any LICENSED SERVICE(S) as the case may be in any 
  

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
particular country, Company shall establish and maintain, in each country in which Company, an AFFILIATED COMPANY or SUBLICENSEE shall test or sell LICENSED PRODUCT(S) and LICENSED SERVICE(S),
product liability or other appropriate insurance coverage in the minimum amount of five million dollars ($5,000,000) per claim and will annually present evidence to JHU that such coverage is being maintained. Upon JHU’s request, Company will
furnish JHU with a Certificate of Insurance of each product liability insurance policy obtained. JHU shall be listed as an additional insured in Company’s said insurance policies. If such Product Liability insurance is underwritten on a
‘claims made’ basis, Company agrees that any change in underwriters during the term of this Agreement will require the purchase of ‘prior acts’ coverage to ensure that coverage will be continuous throughout the term of this
Agreement. 
 9.10 JHU may publish manuscripts, abstracts or the like describing the PATENT RIGHTS and inventions contained therein provided
Confidential Information of Company as set forth in Paragraph 5.3, is not included or without first obtaining approval from the Company to include such Confidential Information. If Company believes that a disclosure of patentable, Company-provided
material is contained in the proposed publication, JHU agrees to withhold publication and disclosure of such materials until a patent application is filed. JHU and the Inventors shall be free to publish manuscripts and abstracts or the like directed
to the work done at JHU related to the licensed technology without prior approval. 
 9.11 This Agreement, including the exhibits hereto,
constitutes the entire understanding between the parties with respect to the obligations of the parties with respect to the subject matter hereof, and supersedes and replaces all prior agreements, understandings, writings, and discussions between
the parties relating to said subject matter. 
  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 9.12 This Agreement may be amended and any of its terms or conditions may be waived only by a
written instrument executed by the authorized officials of the parties or, in the case of a waiver, by the party waiving compliance. The failure of either party at any time or times to require performance of any provision hereof shall in no manner
affect its right at a later time to enforce the same. No waiver by either party of any condition or term in any one or more instances shall be construed as a further or continuing waiver of such condition or term or of any other condition or term.

 9.13 This Agreement shall be binding upon and inure to the benefit of and be enforceable by the parties hereto and their respective
successors and permitted assigns. 
 9.14 Upon termination of this Agreement for any reason, Paragraphs 5.3, 8.3, 9.6, 9.7, 9.8 and 9.9
shall survive termination of this Agreement. 
 9.15 This Agreement is expressly conditioned upon the prior written approval of PHS of
those provisions relating to the JHU/NIH MELANOMA PATENT APPLICATION and LICENSED MELANOMA PRODUCTS and LICENSED MELANOMA SERVICES. 

9.16 The relationship of JHU and Company established by this Agreement is that of independent contractors. Nothing in this Agreement shall be
construed to create any other relationship between JHU and Company. Neither party shall have any right, power or authority to assume, create or incur any expense, liability or obligation, express or implied, on behalf of the other. 

 
 [*] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 9.17 Except as expressly provided herein, each party agrees not to disclose any financial terms
of this Agreement to any third party without the consent of the other party, except as required by securities or other applicable laws, to prospective and other investors, prospective and actual collaborators and such party’s accountants,
attorneys and other professional advisors. 
 9.18 In the event either party hereto is prevented from or delayed in the performance of any
of its obligations hereunder by reason of acts of God, war, strikes, riots, storms, fires, or any other cause whatsoever beyond the reasonable control of the party, the party so prevented or delayed shall be excused from the performance of any such
obligation to the extent and during the period of such prevention or delay. 
 9.19 EXCEPT WITH RESPECT TO EACH PARTY’S LIABILITY FOR
INDEMNIFYING THE OTHER AS PROVIDED HEREIN, NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY FOR ANY SPECIAL, CONSEQUENTIAL, EXEMPLARY OR INCIDENTAL DAMAGES (INCLUDING LOST OR ANTICIPATED REVENUES OR PROFITS RELATING TO THE SAME), ARISING FROM ANY
CLAIM RELATING TO THIS AGREEMENT, WHETHER SUCH CLAIM IS BASED ON CONTRACT, TORT (INCLUDING NEGLIGENCE) OR OTHERWISE, EVEN IF AN AUTHORIZED REPRESENTATIVE OF SUCH PARTY IS ADVISED OF THE POSSIBILITY OR LIKELIHOOD OF SAME. 

 
 [*] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 IN WITNESS WHEREOF the respective parties hereto have executed this License Agreement by their
duly authorized officers on the date appearing below their signatures. 
  

					
	THE JOHNS HOPKINS UNIVERSITY				BIOSANTE PHARMACEUTICALS, INC
			
	 /s/ Glen L. Steinbach
				 /s/ Stephen M. Simes

	Glen L. Steinbach				Stephen M. Simes
	Senior Director				President and CEO
	Johns Hopkins Technology Transfer				
			
	 2/28/11
				 3/3/11

	(Date)				(Date)

  
 [*] = Certain confidential information contained in
this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 EXHIBIT “A” 

JHU/WHITEHEAD PATENTS (DM-9769) 
 [
* ] 
 EXHIBIT “A” (continued) 

JHU ALLOGENEIC PARACRINE PATENT APPLICATIONS (DM-3007) 

[ * ] 
 EXHIBIT
“A” (continued) 
 JHU/NIH MELANOMA PATENT APPLICATION (JHU DM-3096) 

[ * ] 
  

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 EXHIBIT “B” 

<9 pages omitted> 
 [ * ] 

 
 [*] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 EXHIBIT “C” 

National Institutes of Health Consent 
  

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 

 
 Via Federal Express 

May 8, 2000 
 Nina Ossanna, Ph.D. 

Director, Office of Technology Licensing 
 The Johns Hopkins
University School of Medicine  
 111 Market Place, Suite 906 

Baltimore, MD 21202 
 Dear Dr. Ossanna: 

This letter serves to provide you with the written approval of the NIH for the granting of exclusive license to Cell Genesys by The Johns Hopkins
University for U.S. Patent Applications Serial No. [ * ] and Serial No. [ * ], entitled “Melanoma Cell Lines xpreasing Shared lmmunodominant Melanoma Antigens and Methods of Using Same”, and including any divisions or
continuations thereof, all foreign counterpart applications, and any patents issued thereon or reissues or extensions thereof; as per the draft license agreement which was submitted rn the NTH Office of Technology Transfer via electronic mail
on May 1, 2000. 
 In granting this approval, NIH recognizes that The Johns Hopkins University is in compliance with the portion of Paragraph 5.3 of
PHS Interinstitutional Agreement Reference No. L-045-97/0, which states thal “Thc institution [i.e. The Johns Hopkins University] shall not grant any licenses or sublicenses for the Tnvention(s) without first submitting the license or
sublicense agreement: to PHS for review and obtaining PHS’s written approval thereon”. ft is our understanding that, also per Paragraph 5.3 of L-045.97/0, The Johns Hopkins University will
provide PHS with a copy of the license with Cell Gencsys once it has been executed, It is also our understanding that PHS will be provided with any subliccnses for review and written approval prior to their execution. 

Please let me know if you have any questions or require additional information. 

Sincerely, 
  

	
	/s/ Jack Spiegel
	Jac Spiegel, Ph.D,, Director

 Division of Technology Development and Transfer 

Office of Technology Transfer 
 National Institutes of Health 

 
 [*] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00241-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00241-of-00352.parquet"}]]